

2. Mitteilungsblatt

Nr. 2

Mitteilungsblatt der Medizinischen Universität Wien
Studienjahr 2020/2021
2. Stück; Nr. 2

Bevollmächtigungen

2. Bevollmächtigungen gem. § 27 Abs. 2 UG

2. Bevollmächtigungen gem. § 27 Abs. 2 UG

Gemäß § 27 Abs. 2 UG wurden seit 01.01.2020 folgende Bevollmächtigungen erteilt:

Auftragsnummer	Projekttitel	Projektleiter(in)	Organisationseinheit
	VER-CLBP-001	Sator-Katzenschlager Sabine	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738
	Förderung zur Forschungs- und Lehrtätigkeit	Rössler Bernhard	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738
FA738C0204	Investigation of inflammatory parameters in a perioperative closed-meshed standard progress in CPB patients ("ProFil6 Study")	Bernardi Martin Hermann	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738
FA738A0807	ICU4Covid - Number101016000	Kimberger Oliver	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738
FA738A1306	Recombinant human angiotensin- converting enzyme 2 (rhACE2) as a treatment for patients with COVID- 19	Ullrich Roman	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738
FA738A2401	19-515 "Prospective, Open-label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor Who Require Urgent Surgery	Gratz Johannes	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738
	Eine prospektive, randomisierte, doppelblinde, Placebo kontrollierte Studie zur Evaluierung von Landiololhydrochlorid in der Prävention von Vorhofflimmern bei Patienten mit Herzoperation	Steinlechner Barbara	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738
FA738A2301	Acute Kidney Injury in Post- operative ICU	Faybik Peter	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738
FA738A1307	Hinweisgestütztes Beatmungsmanagement zur Verhinderung des Akuten Lungenversagens - ALARM Studie	Ullrich Roman	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738
FA738A1306	Recombinant human angiotensin- converting enzyme 2 (rhACE2) as a treatment for patients with COVID- 19	Ullrich Roman	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738

FA738A1308	Safety and efficacy of inhaled pegylated adrenomedullin (PEG-ADM) in patients suffering from Acute Respiratory Distress Syndrome (ARDS): a double-blind, randomized, placebo-controlled, multicenter Phase 2a/b clinical trial	Ullrich Roman	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738
	Kooperation Digital Health and Patient Safety	Kimberger Oliver	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738
FA738A2301	Acute Kidney Injury in Post-operative ICU	Faybik Peter	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738
FA738C0901	Observational cohort study to characterise the current use of parenteral nutrition and clinical outcomes in adult critically ill patients hospitalised in intensive care units in Europe	Zapletal Bernhard	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738
UE73806004	Ludwig Boltzmann Institut für Digital Health and Patient Safety - O. Kimberger	Markstaller Klaus	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738
FA738C0801	Evaluation des Ventilation-Perfusion-Verhältnisses mittels sequential gas delivery in mechanisch beatmeten Schweinen	Tschernko Edda	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738
FA611A0104	Hochauflösende 3D Darstellung molekularer Signale mit HREM	Weninger Wolfgang	Anatomie und Zellbiologie_310
FA613A0503	SFB 80 RNAdeco: decorating RNA for a purpose/ Koordinationsprojekt 01	Jantsch Franz-Michael	Anatomie und Zellbiologie_310
FA613A0502	SFB 80 RNAdeco: decorating RNA for a purpose/ Teilprojekt 07: Molekulare Konsequenzen der Adenosine Desaminierung	Jantsch Franz-Michael	Anatomie und Zellbiologie_310
FA613A0601	SFB 80 RNAdeco: decorating RNA for a purpose/ Teilprojekt 13: Modifikationen im strukturellen Zentrum mitochondrialer tRNAs	Rossmannith Walter	Anatomie und Zellbiologie_310
FA613A0701	SFB 80 RNAdeco: decorating RNA for a purpose/ Teilprojekt 14: Struktur-Funktionsuntersuchungen an Spezifischen tsRNAs	Schäfer Matthias	Anatomie und Zellbiologie_310
FA613A0801	SFB 80 RNAdeco: decorating RNA for a purpose/ Teilprojekt 15: tRNA-Modifikationslandschaften und ihr Einfluss auf die Translation	Vilardo Elisa	Anatomie und Zellbiologie_310
FA618A0601	Mimicking isoform-specific inhibitors- Genetic engineering of histone deacetylases	Seiser Christian	Anatomie und Zellbiologie_310
	Christian Doppler Labor für Künstliche Intelligenz in der Netzhaut	Bogunovic Hrvoje	Augenheilkunde und Optometrie_746
FA746A0280	AI analysis of HAWK & HARRIER studies	Schmidt-Erfurth Ursula	Augenheilkunde und Optometrie_746

FA746A0281	A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION	Schmidt-Erfurth Ursula	Augenheilkunde und Optometrie_746
FA746A0282	A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION	Schmidt-Erfurth Ursula	Augenheilkunde und Optometrie_746
FA746A2505	Post-hoc imaging review for detection of potential imaging signs of inflammation	Gerendas Bianca	Augenheilkunde und Optometrie_746
FA746A0277	A Post-Authorization, Multicenter, Multinational, Longitudinal, Observational Safety Registry Study for Patients Treated with Voretigene Neparvovec	Schmidt-Erfurth Ursula	Augenheilkunde und Optometrie_746
FA746A1634	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis	Sacu Gülhan Stefan	Augenheilkunde und Optometrie_746
FA746A1503	YOSEMITE GR40349 - a phase III, multicenter, randomized, doublemasked, active comparator controlled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema	Pollreis Andreas	Augenheilkunde und Optometrie_746
FA746A0258	"An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular degeneration (nAMD)"	Schmidt-Erfurth Ursula	Augenheilkunde und Optometrie_746
FA746A3401	Filly Trial	Bogunovic Hrvoje	Augenheilkunde und Optometrie_746
FA746A0279	A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA	Schmidt-Erfurth Ursula	Augenheilkunde und Optometrie_746

FA746A0314	Different IOL-Designs for a cornea with a spherical aberration with +17 μ m	Pieh Stefan	Augenheilkunde und Optometrie_746
FA746A0278	GLEAM & GLIMMER: A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME); BEACON: A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO); GLOW: A Phase 3, Prospective, Randomized, Double-masked, Sham Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Participants with Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR)	Schmidt-Erfurth Ursula	Augenheilkunde und Optometrie_746
FA746A3302	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension	Funk Marion	Augenheilkunde und Optometrie_746
FA746A3104	General Research Funding	Leydolt Christina	Augenheilkunde und Optometrie_746
FA746A1504	The Human Foveal Connectome	Pollreis Andreas	Augenheilkunde und Optometrie_746
FA746A1633	An open-label multi-cohort Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations	Sacu Gülhan Stefan	Augenheilkunde und Optometrie_746
FA746A1626	A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease	Sacu Gülhan Stefan	Augenheilkunde und Optometrie_746

FA746A1625	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease	Sacu Gülhan Stefan	Augenheilkunde und Optometrie_746
FA746A1624	Multicenter, randomized, double blind, placebo controlled study of oral ozanimod as induction therapy for moderately to severely active Crohn's disease	Sacu Gülhan Stefan	Augenheilkunde und Optometrie_746
FA746A0316	General Research Funding - Funding Agreement	Pieh Stefan	Augenheilkunde und Optometrie_746
FA746A2604	Eine offene, multizentrische, externe Placebo-kontrollierte Studie der Phase III zur Beurteilung der Wirksamkeit und Sicherheit von Ravulizumab bei erwachsenen Patienten mit Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD)	Pemp Berthold	Augenheilkunde und Optometrie_746
FA746A0319	General Research Funding - Funding Agreement 2020/2	Pieh Stefan	Augenheilkunde und Optometrie_746
FA746A0277	A Post-Authorization, Multicenter, Multinational, Longitudinal, Observational Safety Registry Study for Patients Treated with Voretigene Neparvovec	Schmidt-Erfurth Ursula	Augenheilkunde und Optometrie_746
FA746A2006	An extension study to evaluate the long-term outcomes of subjects who received treatment for retinopathy of prematurity in Study 20090	Stifter Eva	Augenheilkunde und Optometrie_746
FA746A1632	A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement	Sacu Gülhan Stefan	Augenheilkunde und Optometrie_746
FA746A1626	A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease	Sacu Gülhan Stefan	Augenheilkunde und Optometrie_746
FA746A1625	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease	Sacu Gülhan Stefan	Augenheilkunde und Optometrie_746

FA746A1624	Multicenter, randomized, double blind, placebo controlled study of oral ozanimod as induction therapy for moderately to severely active Crohn's disease	Sacu Gülhan Stefan	Augenheilkunde und Optometrie_746
FA746A0276	An Eighteen-Month, Two-Arm, Randomized, DoubleMasked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolicizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion	Schmidt-Erfurth Ursula	Augenheilkunde und Optometrie_746
FA746A2005	Open-label, randomized, two-arm, controlled study to assess the efficacy, safety, and tolerability of intravitreal (IVT) aflibercept compared to laser photocoagulation in patients with retinopathy of prematurity (ROP)	Stifter Eva	Augenheilkunde und Optometrie_746
FA746A3401	Filly Trial	Bogunovic Hrvoje	Augenheilkunde und Optometrie_746
FA746A1312	General Research Funding: Rotational stability of Nanex IOL	Menapace Rupert	Augenheilkunde und Optometrie_746
FA746A0417	Vienna Preserflo Microshunt Cohort Study	Vass Clemens	Augenheilkunde und Optometrie_746
FA746A0315	Comparing the Primus-HD lens design with different IOL-Designs using an optical bench	Pieh Stefan	Augenheilkunde und Optometrie_746
FA746A3103	General Research Funding - Funding Agreement	Leydolt Christina	Augenheilkunde und Optometrie_746
FA746A0258	"An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular degeneration (nAMD)"	Schmidt-Erfurth Ursula	Augenheilkunde und Optometrie_746
FA746A1631	A 64-week, two-arm, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of brolicizumab 6 mg compared to aflibercept 2 mg in a treat-to-control regimen in patients with neovascular age-related macular degeneration	Sacu Gülhan Stefan	Augenheilkunde und Optometrie_746
FA746A0275	A one-year, single-arm, open-label, multicenter study assessing the anatomic outcomes of brolicizumab assessed by OCT-A in adult patients with neovascular age related macular degeneration	Schmidt-Erfurth Ursula	Augenheilkunde und Optometrie_746

FA746A0318	General Research Funding Ophthamo Pro	Pieh Stefan	Augenheilkunde und Optometrie_746
FA746A2804	A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations.	Dunavölgyi Roman	Augenheilkunde und Optometrie_746
FA746A0241	A multicenter, randomized, double- blind, parallel-group, placebo- controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312)	Schmidt-Erfurth Ursula	Augenheilkunde und Optometrie_746
FA654A0101	Implementierung eines österreichischen 3R Zentrums mit einem Teilstandort an der Medizinischen Universität Wien	Plasenzotti Roberto	Biomedizinische Forschung_308
FA662A0313	Hämostase	Bergmeister Helga	Biomedizinische Forschung_308
FA662A0402	Computational and Experimental Drug Repurposing	Podesser Bruno Karl	Biomedizinische Forschung_308
FA662A0501	Barrieren abbauen - was uns bewegt	Kramer Anne-Margarethe	Biomedizinische Forschung_308
FA727A0612	A Phase 2, Open-label, Single-arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects with Relapsed or Refractory Indolent B- cell Non-Hodgkin Lymphoma (NHL)	Worel Nina	Blutgruppenserologie und Transfusionsmedizin_727
FA727A0605	Plerixafor for stem cell mobilization in patients with multiple myeloma who mobilize moderate to optimize collection results	Worel Nina	Blutgruppenserologie und Transfusionsmedizin_727
FA727A0802	Randomized, Placebo-controlled, double blind multi-centre Phase IIb study to evaluate the efficacy and safety of HepaStem in patients with Acute on Chronic Liver Failure (ACLF)-DHELIVER	Leitner Gerda	Blutgruppenserologie und Transfusionsmedizin_727
FA727A0610	Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein- Barr Virus-Associated Post- Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy	Worel Nina	Blutgruppenserologie und Transfusionsmedizin_727
FA727A0611	PROCESS TRANSFER AND VALIDATION OF APN401	Worel Nina	Blutgruppenserologie und Transfusionsmedizin_727
FA727A0901	A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia	Körmöczy Günther	Blutgruppenserologie und Transfusionsmedizin_727

FA727A0610	Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy	Worel Nina	Blutgruppenserologie und Transfusionsmedizin_727
FA731C1409	Educational Grant: Advanced training in surgical therapy of congenital heart valve defects	Zimpfer Daniel	Chirurgie_731
FA731C1410	Educational Grant - Heart Failure Personal - Anstellungskosten	Zimpfer Daniel	Chirurgie_731
FA731E0609	GRAFALON for Induction Therapy in Liver Transplantation (GRIL)	Berlakovich Gabriela	Chirurgie_731
FA731T0502	Combined low-dose everolimus and low-dose tacrolimus after alemtuzumab induction therapy: a randomized prospective trial in lung transplantation	Jaksch Peter	Chirurgie_731
	Pankreasregister Österreich	Sahora Klaus	Chirurgie_731
FA731E0211	Cell therapy approaches for allergy prevention	Wekerle Thomas	Chirurgie_731
FA731C2204	Prospective, Randomized, Open, Comparison Study to Demonstrate the Performance and the Safety of Cardiac Microcurrent Therapy (C-MIC) System	Wiedemann Dominik	Chirurgie_731
FA731B2601	Präklinische Evaluation der Anwendbarkeit von Tumorzellen nach dem Renale Prinzip bei weiteren Tumorentitäten	Silberhumer Gerd	Chirurgie_731
FA731B1803	"RETHINK REFLUX Registry - Research to further inform thinking about the role of LINX for Reflux Disease"	Schoppmann Sebastian	Chirurgie_731
FA731B2001	Pancreatic Cancer Registry	Schindl Martin	Chirurgie_731
FA731C2102	Intuity Database	Andreas Martin	Chirurgie_731
FA731B2502	Development and Evaluation of Cancer Immune Therapies with Malignant Ascites from Ovarian and Pancreatic Cancer	Pils Dietmar	Chirurgie_731
FA731T0601	The molecular biological signalling of the trepostinil's anti-fibrotic action in idiopathic pulmonary fibrosis	Lambers Christopher	Chirurgie_731
FA731E0701	The impact of iron homeostasis on liver regeneration - a pilot study	Schwarz Christoph	Chirurgie_731
FA731B2201	Efficacy of NHS-PEG coated collagen patch (Hemopatch) for prevention of bile leaks after liver resection - a power analysis.	Schwarz Christoph	Chirurgie_731

	RETHINK REFLUX Registry - Research to further inform thinking about the role of LINX for Reflux Disease"	Schoppmann Sebastian	Chirurgie_731
FA731B0212	Neoadjuvant Chemoradiotherapy with sequential Ipilimumab and Nivolumab in REctal cancer (CHINOREC): a prospective randomized, open-label, multicenter, phase II clinical trial	Bergmann Michael	Chirurgie_731
FA731B2102	A multicenter, randomized, double blind placebo controlled trial of Micronized purified Flavonoid-Fraction (MPFF) in the management of radiation proctitis	Riss Stefan	Chirurgie_731
FA731D0101	The effect of BET inhibitor BI894999 on SCLC cell lines and human CTCs from SCLC patients,	Hamilton Gerhard	Chirurgie_731
FA731B2501	Development and Evaluation of Cancer Immune Therapies with Malignant Ascites from Ovarian and Pancreatic Cancer	Pils Dietmar	Chirurgie_731
FA731C1411	Produktbeobachtungsstudie - Apogee International - Deutsch / Product Surveillance Registry – Mechanical Circulatory Support (MCS) and its Apogee International Addendum	Zimpfer Daniel	Chirurgie_731
FA731C1412	Forschungsförderung GIGAX Stiftung	Zimpfer Daniel	Chirurgie_731
FA731B0213	Tumor explant cultures to test immuno-oncological drugs (BI compounds) alone and in combinations with other anti-tumor drugs or treatments	Bergmann Michael	Chirurgie_731
FA731C1405	Heartmate 3 Registry: Evaluating the HeartMate3™ with Full MagLev Technology in a Post-Market Approval Setting (ELAVATE™)	Zimpfer Daniel	Chirurgie_731
FA731C2113	A multicenter, prospective, randomized, parallel-controlled study to assess Mitral valve reconstruction for advanced insufficiency of functional or ischemic origin (MATTERHORN)	Andreas Martin	Chirurgie_731
FA731T0507	Multicenter analysis of efficacy and outcomes of extracorporeal photopheresis as treatment of chronic lung allograft dysfunction	Jaksch Peter	Chirurgie_731
FA731C2112	MINERVA First-In-Human Clinical Study for Treatment of Severe Mitral Valve Insufficiency with Epygon™ Transcatheter Mitral Valve System - (MINERVA FIH)	Andreas Martin	Chirurgie_731

FA731C2301	Pumpe für ECCO2R - Anteil Herzchirurgie	Granegger Marcus	Chirurgie_731
FA731T0501	Prophylaktische Anwendung der Extrakorporalen Photopherese nach Lungentransplantation - eine prospektive randomisierte Studie	Jaksch Peter	Chirurgie_731
	Trax&Fields-05	Fitzal Florian	Chirurgie_731
FA731C2111	Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Dosisfindungsstudie der Phase II zur Beurteilung der Wirksamkeit und Sicherheit von Botulinumtoxin Typ A-Injektionen (AGN 151607) in das epikardiale Fettgewebe, um postoperatives Vorhofflimmern bei Patienten zu vermeiden, die sich einer Herzoperation am offenen Brustkorb unterziehen	Andreas Martin	Chirurgie_731
FA731D0102	BET-SCLC Amendment 2	Hamilton Gerhard	Chirurgie_731
FA731C2110	QPI-1002 Phase III zur Vorbeugung von MAKE bei Patienten mit hohem Risiko für AKI nach Herzoperation; QPI-1002 Phase 3 for Prevention of MAKE in Subjects at High Risk for AKI Following Cardiac Surgery	Andreas Martin	Chirurgie_731
FA731T0506	Viral load guided Immunosuppression after Lung Transplantation An open-label, randomized, controlled, parallel-group, multicenter trial	Jaksch Peter	Chirurgie_731
FA731T0702	A phase III, double blind, placebo-controlled, multi-center international study of neoadjuvant Durvalumab for the treatment of patients with resectable stages II and III non-small cell lung cancer (AEGEAN)	Hoda Mir Ali Reza	Chirurgie_731
FA731B2302	Protocol 20050209/ABCSG 18; Amendment 4-Zoledronic Acid Substudy	Fitzal Florian	Chirurgie_731
FA731T0505	A Phase III, Multicenter, Open-Label, Extension Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI Investigational eFlow® Device plus Standard of Care in the Treatment of Bronchiolitis Obliterans Syndrome in Patients post Single or Double Lung Transplantation	Jaksch Peter	Chirurgie_731
FA731C2203	Forschungsprojekt Xenios: "Efficassy i-cor-synchronised cardiac assist"	Wiedemann Dominik	Chirurgie_731

FA731B2002	Establishment of a Comprehensive Cancer Center Pancreatic Cancer Registry	Schindl Martin	Chirurgie_731
FA731B2001	Pancreatic Cancer Registry	Schindl Martin	Chirurgie_731
	Protocol 20050209/ABCSG18; Amendment VI – Zoledronic Acid Substudy	Frank Natalija	Comprehensive Cancer Center_2011
	Real world data of all IL-6 routine measurements in neonates (<28 days of age)	Berger Angelika	Comprehensive Center for Pediatrics_2013
FA722C0435	A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection”	Rieger Armin	Dermatologie_722
FA722A0803	Allergen molecules in allergic skin disease: From pathomechanisms to diagnosis and treatment.	Weninger Wolfgang Peter	Dermatologie_722
FA722A0402	Mastzellen	Tschachler Erwin	Dermatologie_722
FA722A0401	Skinbarrier	Tschachler Erwin	Dermatologie_722
FA722A0403	Single cell analysis from skin of volunteers of 2 different age groups	Tschachler Erwin	Dermatologie_722
FA722C1407	A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis who have Experienced Failure to Cyclosporine or are Intolerant to, or have Contraindication to Cyclosporine.	Bangert Christine	Dermatologie_722
FA722C0433	A Phase III Multicenter, Open-Label, Randomized, Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) (MK1439A-024)	Rieger Armin	Dermatologie_722
FA722A0504	A multicenter, double-blind, randomized withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa“ - interner Studiencode CAIN457M2301E1	Jonak Constanze	Dermatologie_722

FA722C1412	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis.	Bangert Christine	Dermatologie_722
FA722B1135	Pan Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab	Höller Christoph	Dermatologie_722
FA722A1201	Die Beurteilung von experimentellen artifiziiell intelligenten (AI) Algorithmen für die Diagnose von Hauttumoren im Vergleich zur menschlichen Leistung	Sinz Christoph	Dermatologie_722
FA722B2306	Einfluss der NETose in der Gewebsregeneration	Mildner Michael	Dermatologie_722
CD10272202	CD-Labors für Multimodales Analytisches Imaging von Alterung und Seneszenz der Haut	Gruber Florian	Dermatologie_722
FA722A1001	A randomized, double-blind, placebo-controlled multicenter dose-ranging study to assess the safety and efficacy of multiple oral ZPL389 doses in patients with moderate to severe atopic dermatitis (ZEST trial).	Brunner Patrick	Dermatologie_722
FA722A0503	Psoriasis Study of Health Outcomes (PSoHO) – an International Observational Study of 3-Year Health Outcomes in the Biologic Treatment of Moderate-to-Severe Plaque Psoriasis.	Jonak Constanze	Dermatologie_722
CD10272201	Christian Doppler Labor für Biotechnologie der Hautalterung / Modul 2 "Environmental and endogenous mechanisms of skin aging" Gesamtprojektleitung und Modul 1 sind an der Universität f. Bodenkultur angesiedelt (Prof. Johannes Grillari)	Gruber Florian	Dermatologie_722
FA722C1411	A multi-center, double-blinded and open-label extension study to evaluate the efficacy and safety of ligelizumab as retreatment, self-administered therapy and monotherapy in Chronic Spontaneous Urticaria patients who completed studies CQGE031C2302, CQGE031C2303, CQGE031C2202 or CQGE031C1301“ - interner Studiencode CQGE031C2302E1	Bangert Christine	Dermatologie_722

FA722C0904	Unraveling the mechanisms of octenidine dihydrochloride efficacy on human skin.	Elbe-Bürger Adelheid	Dermatologie_722
FA722C1204	An open-label study to evaluate the long-term safety of daily ral BCX7353 in subjects with type I and II hereditary angioedema.	Kinaciyar Tamar	Dermatologie_722
FA722C1702	A randomized, double-blind, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of two different doses of vilaprisan (BAY 1002670) versus placebo in women with symptomatic endometriosis.	Geusau Alexandra	Dermatologie_722
FA722C1701	A randomized, parallel-group, double-blind, double-dummy, active-controlled, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids.f	Geusau Alexandra	Dermatologie_722
FA722B2401	T cell-mediated versus anti-TNF-alpha or anti-IL-17A antibody-induced proliferative response of human dendritic cells in psoriasis.	Tittes Julia	Dermatologie_722
FA722C0904	Unraveling the mechanisms of octenidine dihydrochloride efficacy on human skin.	Elbe-Bürger Adelheid	Dermatologie_722
FA722B2305	Wirkmechanismen des Sekretoms von peripheren mononukleären Zellen in der Gewebsregeneration.	Mildner Michael	Dermatologie_722
FA722B1110	A Phase 3, Randomized, Double Blinded Study of Nivolumab Monotherapy of Nivolumab Combined with Ipilimumab versus Ipilimumab Monotherapy in Subjects with Previously untreated unresectable of Metastatic Melanoma - CA209-067.	Höller Christoph	Dermatologie_722
FA722C1410	A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Maintenance Treatment and Flare Reduction with Crisaborole Ointment, 2%, Once Daily Over 52 Weeks in Pediatric and Adult Participants (Ages 2 Years and Older) with Mild-to-Moderate Atopic Dermatitis, who Responded to Twice Daily Crisaborole Ointment, 2%, Treatment.	Bangert Christine	Dermatologie_722

FA722C0437	A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)™ (MK-8591A-018-Site number 3402)	Rieger Armin	Dermatologie_722
FA722B1134	Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: a multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria – BERING.	Höller Christoph	Dermatologie_722
FA722C0433	A Phase III Multicenter, Open-Label, Randomized, Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) (MK1439A-024)	Rieger Armin	Dermatologie_722
FA722B1107	A Randomized, Open Label Phase 3 Trial of BMS-936558 versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post anti-CTLA-4 Therapy.	Höller Christoph	Dermatologie_722
FA722C0420	Strategic Timing of Antiretroviral Therapy (START)	Rieger Armin	Dermatologie_722
FA722C1401	52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222 / MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis.	Bangert Christine	Dermatologie_722
FA722B1707	Wirksamkeit und Sicherheit von Dimethylfumarat bei Patienten mit Palmoplantarer Pustulose - eine offene Phase II Studie über 24 Wochen.	Radakovic Sonja	Dermatologie_722

FA722B1121	CA224-020 - A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal antibody (BMS-986016) Administered Alone and in Combination with Anti-PD1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors.	Höller Christoph	Dermatologie_722
FA722C0904	Unraveling the mechanisms of octenidine dihydrochloride efficacy on human skin.	Elbe-Bürger Adelheid	Dermatologie_722
FA603A0301	Hirnforschung an Instituten der Kaiser-Wilhelm-Gesellschaft im Kontext nationalsozialistischer Unrechtstaten: Hirnpräparate in Instituten der Max-Planck-Gesellschaft und die Identifizierung der Opfer	Czech Herwig	Ethik, Sammlungen und Geschichte der Medizin_390
FA603A0302	Geschichte der Hämatologie und medizinischen Onkologie in Österreich, ca. 1890 bis 1970	Czech Herwig	Ethik, Sammlungen und Geschichte der Medizin_390
FA751C1205	Video-assisted genetic counselling for hereditary breast and ovarian cancer	Pfeiler Georg	Frauenheilkunde_751
FA751C0667	Austrian BRCA-associated metastatic breast cancer registry	Singer Christian	Frauenheilkunde_751
FA751C0659	A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in the Treatment of High-risk, Stage II-III Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer CheckMate 7FL: CHECKpoint pathway and nivolumab clinical Trial Evaluation 7FL	Singer Christian	Frauenheilkunde_751
FA751C0666	Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer	Singer Christian	Frauenheilkunde_751

FA751C0133	A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients	Reinthaller Alexander	Frauenheilkunde_751
FA751C1603	Clinical response to standard of care for advanced ovarian cancer in real-life setting (RESPONSE)	Polterauer Stephan	Frauenheilkunde_751
FA751C0665	A Phase III, multicenter, randomized, doubleblind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nabpaclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation	Singer Christian	Frauenheilkunde_751
FA751C0663	Validierung von GeneXpert® Brustkrebs-Assays zur Bestimmung von Routinebrustkrebs-Biomarkern (ER, PgR, HER2 und Ki67) und zur Vorhersage des Ansprechens/Stratifizierung der Behandlungserfolge in Stanzbiopsien und chirurgischen Proben der ABCSG-34 Biomarker Kohorte	Singer Christian	Frauenheilkunde_751
FA751C0664	PIK3CA Registry - A descriptive study of PIK3CA mutations in patients with HR+/Her2- advanced breast cancer	Singer Christian	Frauenheilkunde_751
FA751C0513	Gene Expression in Fat Tissue of PCOS Patients Translational Research Austria	Wenzl René	Frauenheilkunde_751
FA751C0211	Tumor Suppressor Protein Aggregation Determines Response to Olaparib	Zeillinger Robert	Frauenheilkunde_751
FA751B0602	The Effectiveness of Real Time Continuous Glucose Monitoring to Improve Glycemic Control and Pregnancy Outcomes in Patients with Gestational Diabetes Mellitus	Göbl Christian	Frauenheilkunde_751

FA751C0648	Real World Evidence Collection Of Effectiveness Data Of First Line Ribociclib In Combination With Endocrine Therapy In Hormone-Receptor Positive (HR+), HER2-Negative (HER2-) Advanced Breast Cancer (aBC) In Austria – REACH AUT	Singer Christian	Frauenheilkunde_751
FA751C0628	A Phase III Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel with or without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer (Brocade3)	Singer Christian	Frauenheilkunde_751
FA751C0134	Non-interventional, multicenter, prospective register study to describe the treatment pattern of platinum-sensitive relapsed epithelial ovarian cancer (ROC) patients in Austria	Reinhaller Alexander	Frauenheilkunde_751
FA751D0710	A double-blind randomized extension study to assess the long-term efficacy and safety of linzagolix in subjects with endometriosis-associated pain	Egarter Hans Christian	Frauenheilkunde_751
FA751C0516	A double-blind randomized extension study to assess the long-term efficacy and safety of linzagolix in subjects with endometriosis-associated pain	Wenzl René	Frauenheilkunde_751
FA751C1602	A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer	Polterauer Stephan	Frauenheilkunde_751
FA751C0648	Real World Evidence Collection Of Effectiveness Data Of First Line Ribociclib In Combination With Endocrine Therapy In Hormone-Receptor Positive (HR+), HER2-Negative (HER2-) Advanced Breast Cancer (aBC) In Austria – REACH AUT	Singer Christian	Frauenheilkunde_751
FA751C0662	Germline BRCAness in patients with ovarien and breast cancer with and without family history	Singer Christian	Frauenheilkunde_751
FA751C0702	Early Detection of Ovarian Cancer using Uterine Lavage and Duplex Sequencing	Speiser Paul	Frauenheilkunde_751

FA751C0634	A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER-2 negative advanced breast cancer with progressed on or after aromatase inhibitor treatment	Singer Christian	Frauenheilkunde_751
FA751C0661	Ribociclib-endocrine combination therapy versus chemotherapy as 1st line treatment in patients with visceral metastatic breast cancer. A multicenter, randomized phase III trial	Singer Christian	Frauenheilkunde_751
FA751C0514	A randomized, double-blind, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of two different doses of vilaprisan (BAY 1002670) versus placebo in women with symptomatic endometriosis	Wenzl René	Frauenheilkunde_751
FA751C0510	A randomized, parallel-group, double-blind, double-dummy, active-controlled, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids	Wenzl René	Frauenheilkunde_751
FA751D0708	A randomized, double-blind, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of two different doses of vilaprisan (BAY 1002670) versus placebo in women with symptomatic endometriosis	Egarter Hans Christian	Frauenheilkunde_751
FA751D0706	A randomized, parallel-group, double-blind, double-dummy, active-controlled, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids	Egarter Hans Christian	Frauenheilkunde_751
FA751C0130	A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB FOR PATIENTS WITH NEWLY DIAGNOSED STAGE III/IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER_RO5541267	Reinhaller Alexander	Frauenheilkunde_751
FA744C0105	APrevent Vocal Implant System (VOIS) zur anpassbaren Behandlung der einseitigen Stimmbandlähmung (UVFP) - eine offene, nicht randomisierte Pilotstudie	Schneider-Stickler Berit	Hals-, Nasen- und Ohrenkrankheiten_744

FA744B0902	Characterisation of the nasal microbiome in patients suffering from non-steroidal anti-inflammatory drugs-exacerbated respiratory disease (N-ERD) – a pilot study	Schneider Sven-Thorben	Hals-, Nasen- und Ohrenkrankheiten_744
FA744B1102	“Phase I study of intratumoral CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma” (“Trial”)	Brunner Markus	Hals-, Nasen- und Ohrenkrankheiten_744
UE74406002	Hörstörungen im Zusammenhang mit Gendefekten	Parzefall Thomas	Hals-, Nasen- und Ohrenkrankheiten_744
UE74406002	Hörstörungen im Zusammenhang mit Gendefekten	Parzefall Thomas	Hals-, Nasen- und Ohrenkrankheiten_744
FA744B0901	eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Parallelgruppenstudie der Phase III zu Wirksamkeit und Sicherheit von Benralizumab bei Patienten mit schwergradigen Nasenpolypen	Schneider Sven-Thorben	Hals-, Nasen- und Ohrenkrankheiten_744
UE74406001	Psychoacoustic evaluation of the auditory perception in cochlear implant patients with electric as well as acoustic stimulation	Riss Dominik	Hals-, Nasen- und Ohrenkrankheiten_744
FA744C0301	Kooperation mit CCP, Beitrag zum CCP Starter-Grant; Der schwierige pädiatrische Atemweg-PatientInnenunsicherheit	Denk-Linnert Doris-Maria	Hals-, Nasen- und Ohrenkrankheiten_744
FA744A0202	Effects of locally applied glucocorticoids and selective glucocorticoid receptor agonists on the inner ear in an animal model	Arnoldner Christoph	Hals-, Nasen- und Ohrenkrankheiten_744
	“Phase I study of intratumoral CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma” (“Trial”)	Brunner Markus	Hals-, Nasen- und Ohrenkrankheiten_744
FA744B1501	Treating allergics for functional iron-deficiency with the dietary supplement ImmunoBON®, part 2	Besser Gerold	Hals-, Nasen- und Ohrenkrankheiten_744
FA744B1402	Comparison of Air Quality and Symptom Data	Gstöttner Wolfgang	Hals-, Nasen- und Ohrenkrankheiten_744
FA620A0102	“Imaging neuronal circuits of the prefrontal cortex during a gambling task”	Klausberger Thomas	Hirnforschung_360
FA627A0601	Using cell-cell interactions to unlock new cancer treatments: Forcing neural crest tumors back on to the developmental path	Adameyko Igor	Hirnforschung_360

FA712A0507	EU H2020 Therapeutic approaches to enhance innate immunity against Tumors - TNT-TUMORS	Sibilia Maria	Innere Medizin I_711
FA712A0508	Therapeutic targeting of EGFR in colorectal cancer as a novel approach to predict and enhance tumor antigenicity and response to checkpoint inhibitors	Sibilia Maria	Innere Medizin I_711
	An external control, observational, retrospective study assessing the effect of avapritinib compared with best available therapy for patients with advanced systemic mastocytosis	Jäger Ulrich	Innere Medizin I_711
	Consulting Services Agreement – JCAR017-BCM-001	Jäger Ulrich	Innere Medizin I_711
FA711B0959	a phase-III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation	Preusser Matthias	Innere Medizin I_711
FA711B0960	An open-label, randomised, phase-III study comparing trifluridine/tipiracil in combination with bevacizumab to trifluridine/tipiracil monotherapy in patients with refractory metastatic colorectal cancer	Preusser Matthias	Innere Medizin I_711
FA711C1007	Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES- ALX0681-C302)	Jäger Ulrich	Innere Medizin I_711
UE71106010	Personalkostenförderung Studieninfrastruktur	Jäger Ulrich	Innere Medizin I_711
FA711B0958	a non-interventional, post-authorization safety study of patients with relapsed or refractory Mantle Cell Lymphoma to further investigate and characterize the association of Lenalidomide with tumor flare reaction and high tumor burden	Preusser Matthias	Innere Medizin I_711

FA711B0919	A Phase 3, Global Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	Preusser Matthias	Innere Medizin I_711
FA711C0385	The dynamic interplay between bleeding phenotype and baseline factor level in moderate and mild hemophilia A and B (DYNAMO)	Pabinger Ingrid	Innere Medizin I_711
FA711B0955	a phase-3, randomized, double-blind study of Pamrevlumab or placebo in combination with Gemcitabine plus Nab-paclitaxel as neoadjuvant treatment in patients with locally advanced resectable pancreatic cancer	Preusser Matthias	Innere Medizin I_711
UE71106002	Register für Patienten mit angeborener Blutgerinnungsstörung - Österr. Hämophileregister	Pabinger Ingrid	Innere Medizin I_711
FA711C1095	A Phase 1b Open-label Study to Investigate the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of adults with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)	Jäger Ulrich	Innere Medizin I_711
FA711D0314	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension	Burgmann Heinz	Innere Medizin I_711
UE71106004	Personalkostenförderung	Jäger Ulrich	Innere Medizin I_711
FA711C1033	A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus venetoclax (Rve) versus obinutuzumab (GA101) plus venetoclax (Gve) versus obinutuzumab (GA101) plus ibrutinib plus venetoclax (GIVE) with previously untreated chronic lymphocytic leukemia (CLL) without Del(17p) or TP53 mutation	Jäger Ulrich	Innere Medizin I_711
UE71206001	Kooperationsvertrag MedUni-CeMM	Loizou Joanna	Innere Medizin I_711

FA711C0632	JHTB-Studie - A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms	Jäger Ulrich	Innere Medizin I_711
FA711A0309	Passender unverwandter versus haploidenter Spender für allogene Stammzelltransplantation bei Patienten mit Akuter Leukämie und mit identischer GvHD Prophylaxe - eine randomisierte prospektive europäische Studie	Watzke Herbert	Innere Medizin I_711
FA711B0954	PROCLAIM: a phase-3, randomized, placebo-controlled, double-blind study of Romiplostim for the treatment of chemotherapy-induced Thrombocytopenia in patients receiving chemotherapy for treatment of non-small cell lung cancer (NSCLC), ovarian cancer or breast cancer	Preusser Matthias	Innere Medizin I_711
FA711C1009	Phase II single-arm "window-of-opportunity" study of a combination of obinutuzumab (GA-101) and venetoclax (ABT-199) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL)	Jäger Ulrich	Innere Medizin I_711
FA711C0670	An open-label, multicentre, phase IIIb study assessing the long-term efficacy and safety of AOP2014 in patients with Polycythemia Vera who previously participated in the PROUD-PV study	Jäger Ulrich	Innere Medizin I_711
FA711C1023	Exploration of the role of PD-1/PD-L1 in CLL microenvironment and identification of responders to pembrolizumab.	Jäger Ulrich	Innere Medizin I_711
FA711C0663	EU FP7 eSMART - HEALTH-2013-INNOVATION-1: Randomised controlled trial to evaluate electronic Symptom Management using the Advanced Symptom Management System (ASyMS) Remote Technology for patients with cancers - FP7 - Health - 2013-Innovation-1	Jäger Ulrich	Innere Medizin I_711
FA711B0905	A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)	Preusser Matthias	Innere Medizin I_711

FA711C1041	Eine multizentrische, unverblindete Phase-I-Studie zur Untersuchung der Sicherheit, Verträglichkeit, Wirksamkeit und Pharmakokinetik von DCC-2618 bei Patienten mit fortgeschrittenen malignen Erkrankungen	Jäger Ulrich	Innere Medizin I_711
FA711C0664	A Placebo-Controlled, Double-Blind, Randomized, Multicenter, Three Arm Phase III Trial to Compare the Efficacy and Safety of Ibrutinib vs. Placebo in Previously Untreated Binet Stage A CLL Patients with Risk of Early Disease Progression	Jäger Ulrich	Innere Medizin I_711
FA711C0644	MPN Mutational Analysis to unravel molecular patterns in early stages of disease, during treatment (incl. Ruxolitinib) and leukemic transformation	Jäger Ulrich	Innere Medizin I_711
FA711C1043	A Phase 2, Single-Arm, Multi-Cohort, Multi-Center Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects with Aggressive B-Cell Non-Hodgkin Lymphoma	Jäger Ulrich	Innere Medizin I_711
FA711C1094	A Phase 2, Open-label, Single-arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)	Jäger Ulrich	Innere Medizin I_711
FA711B0741	TALAPRO-1: A Phase 2, Open-Label, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone	Preusser Matthias	Innere Medizin I_711
FA711B0578	Immunomodulation of pembrolizumab plus docetaxel for the treatment of r/m SCCHN after platinum failure	Preusser Matthias	Innere Medizin I_711
FA711B0465	A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin - RADIANT-4	Preusser Matthias	Innere Medizin I_711

FA711B0732	Supplementary Agreement zu: A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷ Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET)	Preusser Matthias	Innere Medizin I_711
FA711B0735	Geriatric assessment of elderly "UNSUITED" patients receiving trabectedin in first line treatment for advanced soft tissue sarcomas (STS)	Preusser Matthias	Innere Medizin I_711
FA711B0915	A retrospective observational multicenter study on the management and outcome of patients with systemic AL amyloidosis in Europe	Preusser Matthias	Innere Medizin I_711
FA711B0729	A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA®) VERSUS SUNITINIB (SUTENT®) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA	Preusser Matthias	Innere Medizin I_711
FA711B0730	A prospective international multicenter phase II study to evaluate the efficacy, safety and quality of life of oral daily pazopanib in patients with advanced and/or metastatic renal cell carcinoma after previous therapy with checkpoint inhibitor treatment	Preusser Matthias	Innere Medizin I_711
FA711B0733	A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Renal Cell Carcinoma	Preusser Matthias	Innere Medizin I_711

FA711B0731	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR)	Preusser Matthias	Innere Medizin I_711
FA711B0734	NCI-Vertrag zur Studie "A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Renal Cell Carcinoma (TITAN RCC)"	Preusser Matthias	Innere Medizin I_711
FA711A0169	Phase I dose-escalation of S 95005 (TAS-102) in combination with oxaliplatin in metastatic colorectal cancer	Preusser Matthias	Innere Medizin I_711
FA711A0152	A Phase II, Open-label, Study in Subjects with BRAF V600E – Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib	Preusser Matthias	Innere Medizin I_711
FA711B0566	A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in BRCA mutated high risk HER2-negative breast cancer patients who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy (OLYMPIA)	Preusser Matthias	Innere Medizin I_711
FA711B0556	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer with No Prior Systemic Therapy in this Disease Setting	Preusser Matthias	Innere Medizin I_711

FA711B0221	The SBG 2004-1/ABCSG 25 Study (The SÖS-Study) - A randomized phase III study comparing biweekly and tailored epirubicin + cyclophosphamide followed by biweekly tailored docetaxel (dtEC - dtT) (A-arm) vs. Three weekly epirubicin + cyclophosphamide, 5-fluorouracil followed by docetaxel (FEC - T) (B-arm) in lymph node positive breast cancer patients - a continuation of the feasibility part of the SBG 2004-1 study.	Preusser Matthias	Innere Medizin I_711
FA712A0803	Gut MICRObiome-based approach for incorporating new biomarkers into COLOrectal cancer screening	Gsur Andrea	Innere Medizin I_711
FA711C1093	A Phase 2, open-label study to evaluate the long-term safety or oral BCX9930 in subjects with paroxysmal nocturnal hemoglobinuria (PNH)	Jäger Ulrich	Innere Medizin I_711
FA711C1092	A phase 2/3, multicenter randomized study of rituximabgemcitabine-dexamethasone-platinum (r-gdp) with or without selinexor in patients with relapsed/refractory diffuse large b-cell lymphoma (rr dlbcl)	Jäger Ulrich	Innere Medizin I_711
FA711C1091	An observational retrospective cohort study of systemic therapies for relapsed or refractory diffuse large B cell lymphoma (R/R DLBCL), to compare outcomes to those from Tafasitamab + Lenalidomide in the L-MIND study (RE-MIND2)	Jäger Ulrich	Innere Medizin I_711
FA711C1089	A Phase 1b Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Preliminary Efficacy of CC-99282 in Combination with Obinutuzumab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Jäger Ulrich	Innere Medizin I_711
FA711B0528	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer	Preusser Matthias	Innere Medizin I_711

FA711E0101	PROSPEKTIVE BEOBACHTUNGSSTUDIE ZUR ANWENDUNG UND ZU DEN BEHANDLUNGSERGEBNISSEN MIT EINGESTELLTER OPIUMTINKTUR (DROPIZOL®) UNTER BEDINGUNGEN DER TÄGLICHEN PRAXIS	Watzke Herbert	Innere Medizin I_711
FA711B0953	a phase-II, randomized, active- controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have received three cycles of platinum doublet chemotherapy	Preusser Matthias	Innere Medizin I_711
FA711C1088	Randomisierte, doppelblinde Phase III-Studie zur Beurteilung der Sicherheit und Wirksamkeit von Venetoclax in Kombination mit Azacitidin bei Patienten mit neu diagnostiziertem myelodysplastischem Syndrom mit höherem Risiko (MDS mit höherem Risiko)	Jäger Ulrich	Innere Medizin I_711
FA711B0565	A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated with Docetaxel plus Prednisolone Who Have Progressed on Enzalutamide Alone (218698 Prot. 9785-MA-1001)	Preusser Matthias	Innere Medizin I_711
FA711C1090	Establishment of a National Registry of Patients with Paraprotein Driven Diseases in Austria	Jäger Ulrich	Innere Medizin I_711
FA711C1086	Eine Phase-1-Studie zur Bestimmung der Sicherheit, Verträglichkeit, Pharmakokinetik und Pharmakodynamik von BCX9930 in Einzeldosen und Mehrfachdosen bei gesunden Probanden und bei Patienten mit paroxysmaler nächtlicher Hämoglobinurie (PNH)	Jäger Ulrich	Innere Medizin I_711

FA711B0805	Real World Evidence Collection Of Effectiveness Data Of First Line Ribociclib In Combination With Endocrine Therapy In Hormone-Receptor Positive (HR+), HER2-Negative (HER2-) Advanced Breast Cancer (aBC) In Austria – REACH AUT (CLEE011AAT01)	Preusser Matthias	Innere Medizin I_711
FA711B0957	a phase-III, open-label, multicenter, randomized trial of adjuvant Palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone-receptor-positive / HER2-negative resected isolated locoregional recurrence of breast cancer	Preusser Matthias	Innere Medizin I_711
	a phase-III, multicenter, randomized, open-label study comparing Atezolizumab (Anti-PD-L1 antibody) in combination with adjuvant Anthracycline/Axane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer	Preusser Matthias	Innere Medizin I_711
CD10271101	CD-Pilotlabor für Personalisierte Immuntherapie	Preusser Matthias	Innere Medizin I_711
FA711C0653	"REGISTRY TO RECLASSIFY early Thrombozythemia, early Myelofibrosis and Polycythemia Vera sample Studiennummer: CINC424XAT01T"	Jäger Ulrich	Innere Medizin I_711
FA711B0944	a randomized, multicenter, double-blind, placebo-controlled phase-3 study of Nivolumab versus Placebo in combination with Neoadjuvant chemotherapy and adjuvant endocrine therapy in the Treatment of high-risk, stage II-III Estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer checkmate 7FL: checkpoint pathway and Nivolumab clinical trial evaluation 7FL	Preusser Matthias	Innere Medizin I_711
FA711B0951	randomised study to investigate FOLFOXIRI plus Cetuximab vs. FOLFOXIRI plus Bevacizumab as first-line treatment of BRAF-mutated metastatic colorectal cancer AIO KRK-0116 / FIRE-4.5	Preusser Matthias	Innere Medizin I_711
	Copanlisib und Rituximab bei Patienten mit Marginalzonenlymphom, COUP-1	Preusser Matthias	Innere Medizin I_711

FA711B0952	a phase-3, randomized, double-blind study of Nivolumab or placebo in combination with Docetaxel, in men with metastatic castration-resistant prostate cancer	Preusser Matthias	Innere Medizin I_711
FA711B0956	a randomized, double-blind, adaptive, phase-II/III study of GSK3359609 or placebo in combination with Pembrolizumab for first-line treatment of PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma	Preusser Matthias	Innere Medizin I_711
FA711B0950	Neratinib in patients with HER2+ breast cancer: a multi-centric, multi-national, prospective, logitudinal, non-interventional study in Germany and Austria	Preusser Matthias	Innere Medizin I_711
FA711B0716	A PHASE 3, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, STUDY OF THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL/ DEPOT 120 MG PLUS BSC VS. PLACEBO PLUS BSC FOR TUMOR CONTROL IN SUBJECTS WITH WELL DIFFERENTIATED, METASTATIC AND/OR UNRESECTABLE TYPICAL OR ATYPICAL LUNG NEUROENDOCRINE TUMORS	Preusser Matthias	Innere Medizin I_711
FA711B0717	An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin who have progressed on prior treatment	Preusser Matthias	Innere Medizin I_711
FA711B0946	CV8102 - Phase I study of intratumoral CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma	Preusser Matthias	Innere Medizin I_711
FA711C1087	Elotuzumab (E) in combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following autologous stem cell transplant in newly diagnosed multiple myeloma and subsequent maintenance with Elotuzumab and Lenalidomide versus single-agent Lenalidomide, a phase III study by DSMM (Deutsch Studiengruppe Multiples Myelom)	Jäger Ulrich	Innere Medizin I_711

FA711C0379	Freeline FLT-01 Screening/Observational Protocol to Determine Patient Eligibility for Inclusion in AAV Gene Therapy Clinical Trials (ECLIPSE)	Pabinger Ingrid	Innere Medizin I_711
FA711B0726	A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer	Preusser Matthias	Innere Medizin I_711
FA712A1603	Repair of DNA lesions induced by platinum drugs - REAP	Loizou Joanna	Innere Medizin I_711
FA711B0947	a phase-3, randomized, open-label, multicenter study comparing Zanubrutinib (BGB3111) plus Rituximab vs. Bendamustine plus Rituximab in patients with previously untreated Mantle Cell Lymphoma who are ineligible for stem cell transplantation	Preusser Matthias	Innere Medizin I_711
FA711B0948	a phase-II study of Trastuzumab-Deruxtecan in HER2-positive breast cancer, patients with newly diagnosed or progressing brain metastases	Preusser Matthias	Innere Medizin I_711
FA711B0945	an open-label, two-arm, randomized, single-stage phase II study of Atezolizumab in combination with dual HER2 blockage plus epirubicin as neoadjuvant therapy for HER2-positive early breast cancer	Preusser Matthias	Innere Medizin I_711
FA711C1043	A Phase 2, Single-Arm, Multi-Cohort, Multi-Center Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects with Aggressive B-Cell Non-Hodgkin Lymphoma	Jäger Ulrich	Innere Medizin I_711
FA711B0949	Multicenter, randomized, double-blind, placebo-controlled phase III clinical trial to investigate the efficacy and safety of Dronabinol in the improvement of chemotherapy-induced and tumor-related symptoms in patients with locally advanced or metastatic pancreatic cancer during first-line chemotherapy (AGMT_DISCOVER), EudraCT 2019-000616-28	Preusser Matthias	Innere Medizin I_711

FA711C1085	Austrian Myeloma Registry	Jäger Ulrich	Innere Medizin I_711
FA711C0384	SOBI Medical Grant für die Unterstützung des Forschungsprojekts „Investigation of parameters of bone metabolism in people with haemophilia“	Pabinger Ingrid	Innere Medizin I_711
UE71106013	Spende der Amgen GmbH – Personalkostenförderung	Pabinger Ingrid	Innere Medizin I_711
FA711C1048	Phase Ib study of tisagenlecleucel in combination with pembrolizumab in relapsed/refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) patients	Jäger Ulrich	Innere Medizin I_711
FA712A1701	Nebenwirkungen der EGFR zielgerichteten Krebstherapie	Bauer Thomas	Innere Medizin I_711
FA711C1083	Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy	Jäger Ulrich	Innere Medizin I_711
FA711C0383	Long-term treatment of cancer associated VTE: Optimal dose of apixaban: API-CAT STUDY for APixaban Cancer Associated Thrombosis - API-CAT	Pabinger Ingrid	Innere Medizin I_711
FA711D0313	A European, multicentre, non-comparative, non-interventional, prospective clinical registry to evaluate the clinical outcome and safety of the treatment of severely infected patients with fosfomycin i.v.	Burgmann Heinz	Innere Medizin I_711
UE71106012	Unterstützung eines Study Coordinators	Watzke Herbert	Innere Medizin I_711
FA712A0510	Genotoxische Untersuchungen der Wässer einer Versuchsanlage zur Reinigung kommunaler Abwässer mittels Ozon und Aktivkohle Kläranlage	Sibilia Maria	Innere Medizin I_711
FA711C0382	An Open-Label, Multinational, Phase 1/2 Study of the Safety and Dose Escalation of SHP648, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua in Hemophilia B Subjects	Pabinger Ingrid	Innere Medizin I_711
FA711C1082	A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia	Jäger Ulrich	Innere Medizin I_711

FA711C1063	EXPLORER®7/NN7415-4311 – Efficacy and Safety of concizumab prophylaxis in patients with haemophilia A or B with inhibitors	Jäger Ulrich	Innere Medizin I_711
FA711C1081	CADENCE Registry Cold Agglutinin Disease Real World Evidence Registry	Jäger Ulrich	Innere Medizin I_711
FA711C0381	Biomarkers in ITP: “Co-creation and Set-up of the project” (1) and “The impact of treatment choices on biomarkers and vice versa in ITP” (2)	Pabinger Ingrid	Innere Medizin I_711
FA711C1084	Supporting CLL Patients using the Advanced Symptom Management System (ASYMS) Remote Technolog	Jäger Ulrich	Innere Medizin I_711
FA711C1079	ESMART: Supporting Myeloma Patients using the Advanced Symptom Management System (ASYMS) Remote Technology	Jäger Ulrich	Innere Medizin I_711
FA711C1080	Evaluation of certain data regarding the relative efficacy of two interferon 2 alpha for the treatment of polycythemia vera	Jäger Ulrich	Innere Medizin I_711
FA711C1013	A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R CHOP) or with Lenalidomide plus R CHOP (R2 CHOP) in Subjects With Previously Untreated, High Risk Diffuse Large B Cell Lymphoma	Jäger Ulrich	Innere Medizin I_711
FA711C1051	Longitudinal investigation of in vitro and ex vivo thrombin generation in patients with venous thromboembolism	Jäger Ulrich	Innere Medizin I_711
FA711D0312	Three Rapid Diagnostic tests (Point-of-Care) for COVID-19 Coronavirus, improving epidemic preparedness, and foster public health and socio-economic benefits	Burgmann Heinz	Innere Medizin I_711
FA711D0311	Emergency-Call zur Erforschung von COVID-19 im Zuge des Ausbruchs von Sars-CoV-2	Burgmann Heinz	Innere Medizin I_711
FA711A0409	Talente - Praktika für Schülerinnen und Schüler 2020	Knapp Sylvia	Innere Medizin I_711
FA711C0380	Medical Grant für die Unterstützung des Projekts zum Aufbau einer Biobank zur Erfassung und Charakterisierung von Patienten mit primärer Immunthrombozytopenie (ITP) und Evaluierung möglicher prädiktiver Faktoren für den Krankheitsverlauf	Pabinger Ingrid	Innere Medizin I_711

FA712A0909	In-vitro Leistungsbeurteilung des prognostischen Algorithmus OncoMasTR anhand der ABCSG-8 Patientenkohorte	Filipits Martin	Innere Medizin I_711
FA712A0908	Assessment of immune checkpoint-associated biomarkers (PD-L1, PD-L2, IRF1, and CD8A) in formalin-fixed, paraffin-embeded tissue samples in a GeneXpert test cartridge	Filipits Martin	Innere Medizin I_711
FA711B0944	a randomized, multicenter, double-blind, placebo-controlled phase-3-study of Nivolumab versus Placebo in combination with Neoadjuvant chemotherapy and adjuvant endocrine therapy in the Treatment of high-risk, stage II-III Estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer checkmate 7L: checkpoint pathway and Nivolumab clinical trial evaluation 7FL	Preusser Matthias	Innere Medizin I_711
FA711C1078	Prognostic parameters of Patients with MDS and Pre-MDS Conditions	Jäger Ulrich	Innere Medizin I_711
FA711B0941	a phase 3, open-label, randomized, active-controlled, multicenter study to evaluate the efficacy and safety of Pemigatinib versus Gemcitabine plus Cisplatin Chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement	Preusser Matthias	Innere Medizin I_711
FA712A1602	Qualitätskontrolle und DNA-Schäden im Zellkern	Loizou Joanna	Innere Medizin I_711
FA711B0942	eine doppelblinde, "placebokontrollierte" randomisierte Phase-II-Studie zu lpatasertib in Kombination mit Atezolizumab und Paclitaxel als Behandlung für Patienten mit lokal fortgeschrittenem, nicht resektablem oder metastasiertem triple-negativem Brustkrebs	Preusser Matthias	Innere Medizin I_711
FA711B0943	a phase-2-study in first line metastatic or unresectable, recurrent head and neck squamous cell carcinoma to evaluate intratumoral MK-1454 in combination with IV Pembrolizumab vs. IV Pembrolizumab monotherapy	Preusser Matthias	Innere Medizin I_711

FA711B0940	Eine multizentrische, randomisierte, offene, aktiv kontrollierte Phase-III-Studie zu DS-8201a, einem Anti-HER2-Antikörper-Wirkstoff-Konjugat (AWK) im Vergleich zu einer vom Arzt gewählten Behandlung bei Patient*innen mit inoperablem und/oder metastasiertem Brustkrebs mit geringer HER2-Expression.	Preusser Matthias	Innere Medizin I_711
FA711B0939	Ribociclib-endokrine Therapiekombination versus Chemotherapie als Erstlinientherapie bei PatientInnen mit viszeralem Brustkrebsmetastasen. Eine multizentrische, randomisierte Phase-II-Studie	Preusser Matthias	Innere Medizin I_711
FA711C1076	Deciphering resistance to anti-CTL019 CAR-T cell therapy in diffuse large B-cell lymphoma	Jäger Ulrich	Innere Medizin I_711
FA711B0937	IDH mutated 1p/19q intact lower grade glioma following resection: wait or treat? The IWOT phase II study	Preusser Matthias	Innere Medizin I_711
FA712A1601	Dna Damage REsponse: Actionabilities, Maps and Mechanisms	Loizou Joanna	Innere Medizin I_711
FA711B0915	A retrospective observational multicenter study on the management and outcome of patients with systemic AL amyloidosis in Europe	Preusser Matthias	Innere Medizin I_711
FA711D0310	MULTIZENTRISCHE KLINISCHE UNTERSUCHUNG FÜR DIE BEURTEILUNG DER LEISTUNGSFÄHIGKEIT DES DUALDUR IN VITRO DIAGNOSTIKSYSTEMS IN DER DIAGNOSTIK DER LYME-BORRELIOSE AUS BLUTPROBEN VON SOLCHEN PATIENTEN, DIE ENTWEDER THERAPIENAIV SIND ODER BEREITS BEHANDELT WURDEN, UND DEREN BEHANDELNDER ARZT DIE MEDIZINISCHE BEHANDLUNG DER LYME-BORRELIOSE INDIZIERT	Burgmann Heinz	Innere Medizin I_711
UE71106010	Personalkostenförderung Studieninfrastruktur	Jäger Ulrich	Innere Medizin I_711

FA711C1077	A randomized, double-blind, phase 3 study to evaluate the activity of Momelitinib (MMB) versus Danazol (DAN) in symptomatic, anemic subjects with primary myelofibrosis (PMF), post-polycythemia vera (PV) myelofibrosis, or post essential thrombocythemia (ET) myelofibrosis who were previously treated with JAK inhibitor therapy	Jäger Ulrich	Innere Medizin I_711
FA711C1075	A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects with T-Cell Prolymphocytic Leukemia	Jäger Ulrich	Innere Medizin I_711
FA711A0305	GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo on Combination With Corticosteroids for the Treatment of First-Line Acute Graft Versus-Host Disease	Watzke Herbert	Innere Medizin I_711
FA711B0936	a non-interventional study to assess the safety and efficacy of first line therapy with Vectibix® in combination with FOLFIRI or FOLFOX and to validate a prognostic score in adult patients with RAS wild-type metastatic colorectal cancer in a real world setting	Preusser Matthias	Innere Medizin I_711
FA711C1040	Sammlung von Restproben zur technischen Validierung einer in vitro diagnostischen Testplattform in der akuten myeloischen Leukämie	Jäger Ulrich	Innere Medizin I_711
FA711C0289	Funding Agreement - set-up, maintenance and management of the Patient registry of the European Network on Mastocytosis	Jäger Ulrich	Innere Medizin I_711
FA711C1042	A prospective, non-interventional biomedical research study of genetic aberrations and immunity in myeloproliferative neoplasms	Jäger Ulrich	Innere Medizin I_711
FA711C1035	A phase 2, open-label, monotherapy, multicenter study to evaluate the efficacy and safety of INCB54828 in subjects with myeloid/lymphoid neoplasms with FGFR1 rearrangement	Jäger Ulrich	Innere Medizin I_711

FA711C1010	Randomisierte Phase II, 2-Arm Studie bei für Transplantation ungeeignete Patienten mit neu diagnostizierten multiplen Myelom (NDMM) zum Vergleich von Carfilzomib + Thalidomid + Dexamethason (KTD) Induktionstherapie mit Carfilzomib + Lenalidomid + Dexamethason (KRD) Induktionstherapie in Bezug auf Ansprechraten und Untersuchung einer Monotherapie mit Carfilzomib (K) als Erhaltungstherapie	Jäger Ulrich	Innere Medizin I_711
FA711C1056	Treatment Outcomes in Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder after Hematopoietic Cell Transplant or Solid Organ Transplant who have Failed Rituximab or Rituximab Plus Chemotherapy	Jäger Ulrich	Innere Medizin I_711
FA711C0643	A MULTICENTER, PHASE 1B, OPEN-LABEL STUDY TO DETERMINE THE SAFETY AND ACTIVITY OF CC 292 IN COMBINATION WITH LENALIDOMIDE IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA /SMALL LYMPHOCYTIC LYMPHOMA	Jäger Ulrich	Innere Medizin I_711
FA711C0659	A Phase 3 Study of IPI-145 versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Cross over: A Study of IPI-145 and Ofatumumab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07	Jäger Ulrich	Innere Medizin I_711
FA711C0676	"A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)"	Jäger Ulrich	Innere Medizin I_711
FA711C1049	A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia	Jäger Ulrich	Innere Medizin I_711

FA711A0162	A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma	Preusser Matthias	Innere Medizin I_711
FA711A0163	A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma	Preusser Matthias	Innere Medizin I_711
FA711B0559	A randomized, open-label phase III trial evaluating the addition of denosumab to standard first-line anticancer treatment in advanced NSCLC	Preusser Matthias	Innere Medizin I_711
FA711B0574	Axitinib in Advanced / Metastatic Renal Cell Carcinoma - A Non-Interventional Study of Real World Treatment Outcomes in Patients Receiving 2nd Line Axitinib after 1st Line Sunitinib	Preusser Matthias	Innere Medizin I_711
FA711B0715	A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY (IMmotion)	Preusser Matthias	Innere Medizin I_711
FA711B0712	Randomisierte Phase II, 2-Arm Studie bei für Transplantation ungeeignete Patienten mit neu diagnostizierten multiplen Myelom (NDMM) zum Vergleich von Carfilzomib + Thalidomid + Dexamethason (KTD) Induktionstherapie mit Carfilzomib + Lenalidomid + Dexamethason (KRD) Induktionstherapie in Bezug auf Ansprechraten und Untersuchung einer Monotherapie mit Carfilzomib (K) als Erhaltungstherapie (AGMT_M	Preusser Matthias	Innere Medizin I_711
FA711B0718	The Search for Biomarkers to Predict Nivolumab Response in NSCLC: Identification of Genomic Changes	Preusser Matthias	Innere Medizin I_711

FA711B0726	A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer	Preusser Matthias	Innere Medizin I_711
FA711B0572	A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy	Preusser Matthias	Innere Medizin I_711
FA711C0369	JOSEPHA phase 1 (Joint-health Outcome Scoring: Exploration in Patients with Haemophilia in Austria)	Pabinger Ingrid	Innere Medizin I_711
FA711B0725	A randomized, open label, multicenter study of Cabazitaxel versus an Androgen Receptor (AR)-targeted agent (abiraterone or enzalutamide) in mCRPC patients previously treated with Docetaxel and who rapidly failed a prior AR-targeted agent	Preusser Matthias	Innere Medizin I_711
FA711B0519	EVA (evaluation of Votrient® in angiosarcoma): Einarmige, multizentrische offene Phase-II-Studie zur Überprüfung der Wirksamkeit der Kombination von Paclitaxel mit Pazopanib bei fortgeschrittenen und rezidierten Angiosarkomen	Preusser Matthias	Innere Medizin I_711
FA711C1054	Molecular Risk Profiling of TKI-treated Patients with Ph+ CML	Jäger Ulrich	Innere Medizin I_711
FA711C0642	APHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO COMPARE EFFICACY AND SAFETY OF ORAL AZACITIDINE PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE AS MAINTENANCE THERAPY IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA IN COMÖLETE REMISSION	Jäger Ulrich	Innere Medizin I_711
FA711C1017	Sepsis-Associated Purpura Fulminans International Registry – Europe (SAPFIRE)	Jäger Ulrich	Innere Medizin I_711

FA711C1062	Diagnose der fortgeschrittenen systemischen Mastozytose bei Patienten mit Myeloproliferativen Neoplasien	Jäger Ulrich	Innere Medizin I_711
FA712A1102	Bacterial ghosts as immune-stimulating adjuvant to chemotherapy in pancreatic ductaladenocarcinoma	Heffeter Petra	Innere Medizin I_711
FA712A1103	Forschungsgruppe	Heffeter Petra	Innere Medizin I_711
FA711C1074	Eine prospektive, randomisierte, kontrollierte, offene, multizentrische, in zwei Abschnitte gegliederte Crossover-Studie der Phase III mit einer aus einem einzigen Arm bestehenden Fortsetzung zur Beurteilung der Sicherheit und Wirksamkeit von BAX 930 (rADAMTS13) bei der prophylaktischen und Bedarfsbehandlung von Patienten mit schwerer kongenitaler thrombotisch thrombozytopenischer Purpura (cTTP, Upshaw-Schulman-Syndrom USS, hereditäre thrombotisch thrombozytopenische Purpura, hTTP)	Jäger Ulrich	Innere Medizin I_711
FA711B0935	A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving FOLFOX-based Chemotherapy for Treatment of Gastrointestinal or Colorectal Cancer	Preusser Matthias	Innere Medizin I_711
FA711C1073	A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia	Jäger Ulrich	Innere Medizin I_711
FA711C0379	Freeline FLT-01 Screening/Observational Protocol to Determine Patient Eligibility for Inclusion in AAV Gene Therapy Clinical Trials (ECLIPSE)	Pabinger Ingrid	Innere Medizin I_711
FA711C1014	A multicenter phase II, open label, single arm study to evaluate the efficacy and safety of ruxolitinib in the treatment of anemic myelofibrosis patients	Jäger Ulrich	Innere Medizin I_711

FA711C1071	A phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy in subjects with DIPSS-intermediate or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis and previously treated with ruxotinib	Jäger Ulrich	Innere Medizin I_711
FA711B0934	Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma	Preusser Matthias	Innere Medizin I_711
FA711B0465	A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin - RADIANT-4	Preusser Matthias	Innere Medizin I_711
FA711B0578	Immunomodulation of pembrolizumab plus docetaxel for the treatment of r/m SCCHN after platinum failure	Preusser Matthias	Innere Medizin I_711
FA711B0556	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer with No Prior Systemic Therapy in this Disease Setting	Preusser Matthias	Innere Medizin I_711
FA711C1072	AGMT Förderung für das gemeinsame akademische Forschungsprojekt „Seal – Datenanalysen“	Jäger Ulrich	Innere Medizin I_711
FA711B0938	Multizentrische, offene Dosiseskaltungsstudie der Phase I mit ABBV-181 als Monotherapie und in Kombination mit einer weiteren Krebstherapie bei Studienteilnehmern mit fortgeschrittenen soliden Tumoren (M15-891)	Preusser Matthias	Innere Medizin I_711
FA711B0902	STEAM: Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients with Anaplastic Astrocytoma or Glioblastoma: A Phase Ib Study	Preusser Matthias	Innere Medizin I_711

FA711B0807	ABCSG32 / retrospektive Datenanalyse	Steger Günther	Innere Medizin I_711
FA711B0563	MONALEESA-3: A randomized double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment	Preusser Matthias	Innere Medizin I_711
FA711B0553	A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer	Steger Günther	Innere Medizin I_711
FA711B0541	A Phase III study of Palbociclib (PD-0332991) in combination with Exemestane versus chemotherapy (capecitabine) in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patients with Resistance to non-steroidal Aromatase inhibitors	Preusser Matthias	Innere Medizin I_711
FA711C1031	Aufbau einer Biobank zur Erfassung und Charakterisierung von Patienten mit primärer Immunthrombozytopenie und Evaluierung möglicher prädiktiver Faktoren für den Krankheitsverlauf	Pabinger Ingrid	Innere Medizin I_711
FA714B4203	Educational Grant	Hengstenberg Christian	Innere Medizin II_714
	Behandlung von dyslipämischen Patienten mit hohem und sehr hohem Risiko zur Prävention von kardiovaskulären Ereignissen in Europa - eine multinationale Beobachtungsstudie - SANTORINI (NIS)	Scherthner Gerit	Innere Medizin II_714
	Nicht-invasive Gewebscharakterisierung und Denervationserfassung mittels PET-MRT bei Patienten mit Anderson Fabry Erkrankung	Graf Senta	Innere Medizin II_714
FA714B4702	Einfluss der Diabetes-Medikation auf den Krankheitsverlauf in Patienten mit Herzinsuffizienz vom HFpEF-Typ	Badr Eslam Roza	Innere Medizin II_714
FA714C0313	Effects of Semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease; Protocol ID: NN9535-4533	Scherthner Gerit	Innere Medizin II_714
UE71406015	Comprehensive imaging and patient management training with regard to edge-to-edge mitral and tricuspid valve procedures	Mascherbauer Julia	Innere Medizin II_714

FA714B4801	Cardiac specific Effects by SGLT-2 Inhibition in Heart Failure with reduced Ejection Fraction	Arfsten Henrike	Innere Medizin II_714
FA714B4901	A PHASE II, RANDOMIZED, ACTIVE-CONTROLLED, MULTI-CENTER STUDY COMPARING THE EFFICACY AND SAFETY OF TARGETED THERAPY OR CANCER IMMUNOTHERAPY GUIDED BY GENOMIC PROFILING VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH CANCER OF UNKNOWN PRIMARY SITE WHO HAVE RECEIVED THREE CYCLES OF PLATINUM DOUBLET CHEMOTHERAPY	Kastl Stefan	Innere Medizin II_714
FA714C0702	Infusion von Dexamethason in die Adventitia der Unterschenkelgefäße mittels Bullfrog R um das Auftreten einer Re-Stenose nach PTA-Behandlungen zu verringern.	Schlager Oliver	Innere Medizin II_714
FA714B4209	A Phase III, multicenter, randomized, double blind, placebo-controlled study to asses the efficacy and safety alpelisib (BYL719) in combination with nabpaclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation	Hengstenberg Christian	Innere Medizin II_714
FA714B4602	Die präklinische Anwendung von Ticagrelor bei Akutem Koronarsyndrom in Wien	Sulzgruber Patrick	Innere Medizin II_714
FA714B3105	Doppelblinde, randomisierte, placebokontrollierte, multizentrische Phase-3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Vutrisiran bei Patienten mit Transthyretin-Amyloidose mit Kardiomyopathie (ATTR - Amyloidose mit Kardiomyopathie)	Kastner Johannes	Innere Medizin II_714
FA714D0502	A Phase 2b, randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 as maintenance therapy in adult subjects with moderate to severe asthma.	Idzko Marco	Innere Medizin II_714

FA714C0309	„A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care“ und der Bayer-Nummer IMP17530 (FIGARO)	Schernthaner Gerit	Innere Medizin II_714
FA714C0308	"A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease“ und der Bayer-internen Nummer IMP 16244	Schernthaner Gerit	Innere Medizin II_714
FA714B2713	Repatha NIS	Bergler-Klein Jutta	Innere Medizin II_714
FA714B2711	Factor XA-inhibition in RENal patients with non-valvular atrial fibrillation Observational study	Bergler-Klein Jutta	Innere Medizin II_714
FA714B2304	A retrospective-prospective observational study to assess Landiolol utilization patterns in patients with supraventricular tachycardia, for rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter, for short-term control of the ventricular rate, or for non-compensatory sinus tachycardia.	Siller-Matula Jolanta	Innere Medizin II_714
FA714B2905	Herzamyloidose bei TAVI	Mascherbauer Julia	Innere Medizin II_714
FA714B1710	SMART Registry: Strategie Management to Optimize Response To Cardiac Resynchronization Therapy Registry	Gwechenberger Marianne	Innere Medizin II_714
FA714B2715	Postmarket Study - TriageTru	Bergler-Klein Jutta	Innere Medizin II_714
FA714B3104	Eine multizentrische, randomisierte, doppelt-verblindete, Parallelgruppen- und Placebo-kontrollierte Studie zur Untersuchung der Wirksamkeit und Sicherheit von Finerenone bei Patienten mit Herzinsuffizienz (NYHA II-IV) und linksventrikulärer Auswurffraktion $\geq 40\%$ (LVEF $\geq 40\%$), FINEARTS-HF	Kastner Johannes	Innere Medizin II_714

FA714B4701	Eine multizentrische, doppelblinde, dreiarmlige, placebound aktiv kontrollierte Studie der Phase II zur Beurteilung der Wirksamkeit und Sicherheit von Verinurad in Kombination mit Allopurinol bei Herzinsuffizienz mit erhaltener Ejektionsfraktion. (Amethyst)	Badr Eslam Roza	Innere Medizin II_714
FA714B1712	Clinical Study Agreement - OSIRIS	Gwechenberger Marianne	Innere Medizin II_714
FA714B4401	Stress bei medizinischen Personal und Kontrollen	Sponder Michael	Innere Medizin II_714
FA714B0364	Edoxaban versus Versorgungsstandard und deren Wirkungen auf die klinischen Ergebnisse bei Patienten mit Vorhofflimmern nach erfolgreichem Kathetergestütztem Aortenklappenersatz (ENVISAGE TAVI-AF)	Lang Irene	Innere Medizin II_714
FA714B2008	A multicenter, randomized, parallel Group, Double Blind, Active and Placebo Controlled Study of BAY 1753011, a Dual V1a/V2 Vasopressin Receptor Antagonist, in Patients with Congestive Heart Failure: AVANTI Study	Hülsmann Martin	Innere Medizin II_714
FA714B1405	SHERBOC: A Double Blind, Placebo-controlled, Phase 2 trial of Seribantumab Plus Fulvestrant in Postmenopausal Women with Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer whose disease Progressed after prior Systemic Therapie	Gabriel Harald	Innere Medizin II_714
FA714B4208	Spiroergometrie Register zur Evaluierung von prognostischen Faktoren bei Herzerkrankungen – ein monozentrisches, retrospektives und prospektives Register	Hengstenberg Christian	Innere Medizin II_714
FA714B1512	A Randoized Parallel-Group, Placebo-Controlled, Double-lind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFeEF)-Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) (MK1242-001)	Kastner Johannes	Innere Medizin II_714

FA714B4207	Treatment of High and Very high risk dyslipidemic patients for the Prevention of Cardiovascular Events in Europe – a Multinational Observational Study (SANTORINI)	Hengstenberg Christian	Innere Medizin II_714
FA714B2904	Educational Grant - Mitralklappenprogramm	Mascherbauer Julia	Innere Medizin II_714
FA714B4101	Safety of oral anticoagulants in patients with atrial fibrillation and heart failure with preserved ejection fraction	Schrutka Lore	Innere Medizin II_714
FA714B4303	A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease	Speidl Walter	Innere Medizin II_714
FA714B4206	POST-MARKET STUDY (SAPIEN 3 ULTRA SYSTEM PMCF Study #2018-09)	Hengstenberg Christian	Innere Medizin II_714
FA714B1711	Observation of clinical routine care for heart patients implanted with BIOTRONIK CRT devices	Gwechenberger Marianne	Innere Medizin II_714
FA714B0375	Residual Electrical Activity in the Blind Spot of Lasso-Guided Antrum Isolation Detected by Ultra-High-Density Mapping Study	Lang Irene	Innere Medizin II_714
FA714B4601	Der Herzstillstand in Wien im Zeitraum von 2009 bis 2019 – eine Analyse der demographischen Entwicklung sowie Outcome von Patienten mit Herzstillstand des letzten Jahrzehnts	Sulzgruber Patrick	Innere Medizin II_714
FA714B2806	Personalisierte Risikoprädiktion in Patienten mit Diabetes und Prädiabetes	Niessner Alexander	Innere Medizin II_714
FA714B1525	HFpEF Register "Predictors of outcome in heart failure with normal ejection fraction"	Kastner Johannes	Innere Medizin II_714
FA714B1605	Cardiac Manifestation of Fabry Anderson Disease	Graf Senta	Innere Medizin II_714
FA714B4205	MiCLASP: Transkatheter-gestützte Rekonstruktion bei Mitralklappeninsuffizienz mit dem Edwards PASCAL Transkatheter-Mitralklappen-Reparatursystem: Eine europäische, prospektive, multizentrische, klinische Beobachtungsstudie nach Markteinführung	Hengstenberg Christian	Innere Medizin II_714
FA714B2302	Impact of EMPagliflozin on cardiac function and biomarkers of heart failure in patients with acute Myocardial infarction (EMMY-Trial) - a phase III Study	Siller-Matula Jolanta	Innere Medizin II_714

FA714B1524	SPIRonolactone In the Treatment of Heart Failure - SPIRIT-HF	Kastner Johannes	Innere Medizin II_714
FA714B0365	Effects of the PCSK9 Antibody AliroCuMab on Coronary Atherosclerosis in Patients with Acute Myocardial Infarction. A Serial, multivessel, intravascular Ultrasound, near-infrared spectroscopy and optical coherence tomography Imaging Study	Lang Irene	Innere Medizin II_714
FA714C0706	ARIVA: Rivaroxaban plus Aspirin versus Rivaroxaban alone for the prevention of venous stent thrombosis in patients with post-thrombotic-Syndrome.	Schlager Oliver	Innere Medizin II_714
FA714C0602	"A prospective, multicenter, single arm real-world registry investigating the clinical use and safety of the Lutonix drug coated balloon PTA catheter for treatment of below-the knee (BTK) arteries"	Willfort-Ehringer Andrea	Innere Medizin II_714
FA714B0375	Residual Electrical Activity in the Blind Spot of Lasso-Guided Antrum Isolation Detected by Ultra-High-Density Mapping Study	Lang Irene	Innere Medizin II_714
FA714B0536	Gene expression profiling of the heart affected by different anticancer drugs	Pavone-Gyöngyösi Mariann	Innere Medizin II_714
FA714B4204	RHEIA - A Prospective, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Transcatheter Aortic Valve Implantation in Female Patients who have Severe Symptomatic Aortic Stenosis Requiring Aortic Valve Replacement	Hengstenberg Christian	Innere Medizin II_714
	APPROACH-IS II -Assessment of patterns of patient reported outcomes in adults with congenital heart disease - international study II	Gabriel Harald	Innere Medizin II_714
FA714B2805	Real World Data for the Safety of NOACs including Edoxaban	Niessner Alexander	Innere Medizin II_714
FA714B2804	Postoperatives Vorhofflimmern - Risikofaktoren und Outcome	Niessner Alexander	Innere Medizin II_714
FA714B2802	Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub-Clinical Atrial fibrillation	Niessner Alexander	Innere Medizin II_714
FA716F0106	Optimal gender-specific treatment paths on healthcare multiplex networks	Kautzky-Willer Alexandra	Innere Medizin III_716
FA716C0821	Longtime therapy with generic Ciclosporin A	Sunder-Plaßmann Gere	Innere Medizin III_716

FA716B0313	EU H2020 - Neuro-metabolic, structural and functional hallmarks of Lysosomal Storage Diseases - Neuro LSD - H2020-MSCA-IF-2017	Stulnig Thomas	Innere Medizin III_716
	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis	Trauner Michael	Innere Medizin III_716
	An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis	Trauner Michael	Innere Medizin III_716
	Registry for patients with rheumatic diseases at the intensive care unit	Becede Manuel	Innere Medizin III_716
FA716E0939	Targeting mucosal biofilms in patients with gastrointestinal disorders	Trauner Michael	Innere Medizin III_716
FA716E0858	A randomized, multi-center phase III study of Nivolumab versus Sorafenib as first-line treatment in patients with advanced HCC	Trauner Michael	Innere Medizin III_716
FA716E0844	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE	Trauner Michael	Innere Medizin III_716
FA716E0840	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib	Trauner Michael	Innere Medizin III_716
FA716E0838	An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-1)"	Trauner Michael	Innere Medizin III_716
FA716E0830	An open-label extension and safety monitoring study of moderate to severe	Trauner Michael	Innere Medizin III_716

FA716E0945	A randomized, placebo controlled, double-blind, parallel-arm feasibility (pilot) study to evaluate safety and clinical efficacy of G-PUR® treatment in patients with irritable bowel syndrome with diarrhea (IBS-D)	Trauner Michael	Innere Medizin III_716
FA716B1311	Testung der Gebrauchstauglichkeit des verschreibungspflichtigen digitalen Medizinprodukts Klasse 1 "Funnyslim MED App" mittels Durchführung einer Usability Studie.	Krebs Michael	Innere Medizin III_716
FA716E0979	A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis	Trauner Michael	Innere Medizin III_716
FA716B0311	A phase 3 randomized, multicenter, multinational, double-blinded study comparing the efficacy and safety of repeated biweekly infusions of neo GAA (GZ402666) and alglucosidase alfa in treatment naive patients with late onset Pompe disease	Kautzky-Willer Alexandra	Innere Medizin III_716
FA716B0618	Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT)	Kautzky-Willer Alexandra	Innere Medizin III_716
	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE)	Machold Klaus	Innere Medizin III_716
FA716E0978	ACUSON Sequoia Ultrasound System	Trauner Michael	Innere Medizin III_716
FA716E0977	Hepatitis D Virus (HDV) Epidemiology in Austria], entitled "DEPAU"	Trauner Michael	Innere Medizin III_716
FA716B0617	ASSESS-CKD, BAY 2327949	Kautzky-Willer Alexandra	Innere Medizin III_716
FA716B1803	CGMS 2	Winhofer-Stöckl Yvonne	Innere Medizin III_716
UE71606011	Anstellung eines durch Drittmittel finanzierten Dokumentationsassistenten an der Institution um 4 Wochenstunden	Trauner Michael	Innere Medizin III_716

FA716E0975	A Phase 3 randomized open-Label, multicenter Study comparing zanubrutinib (BGB 3111) plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma who are ineligible for stem cell transplantation	Trauner Michael	Innere Medizin III_716
FA716D0809	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of Baricitinib as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects with New-Onset Polymyalgia Rheumatica (JAK-SPARE 1)	Aletaha Daniel	Innere Medizin III_716
FA716D1803	A Registry for patients with rheumatic diseases at the intensive care unit	Becede Manuel	Innere Medizin III_716
FA716D0716	A multicenter, randomized, double-blind, placebo-controlled, dose-finding clinical trial in patients with active psoriatic arthritis to investigate efficacy, tolerability, safety, pharmacokinetics and immunogenicity of ABY-035	Scheinecker Clemens	Innere Medizin III_716
FA716D0808	Updated consensus statement on the use of selective IL-6 inhibitors in the treatment of rheumatoid arthritis	Aletaha Daniel	Innere Medizin III_716
FA716E0976	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis	Trauner Michael	Innere Medizin III_716
FA716D1502	Effekte der prophylaktischen und therapeutischen Anwendung der KSRT auf die Knochendichte und den Knochenstoffwechsel bei gesunden, gealterten und ovariectomierten Mäusen	Hayer Silvia	Innere Medizin III_716
FA716C1018	A randomized, double-blind, parallel group, placebo-controlled, multi-center study to assess the safety and tolerability of monthly subcutaneous administrations of a low and high dose cohort of osocimab to ESRD patients on regular hemodialysis(CONVERT)	Oberbauer Rainer	Innere Medizin III_716

FA716B0612	Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant ¹ to be conducted according to the Protocol.	Kautzky-Willer Alexandra	Innere Medizin III_716
	Molecular control of regulatory T cells by NFIL3	Bonelli Michael	Innere Medizin III_716
FA716B0230	European Pasireotide LAR Observational Study in Acromegaly - ACRONIS Study	Kautzky-Willer Alexandra	Innere Medizin III_716
FA716B0231	""A Phase 3, Randomized, Open-Label, Active Controlled, Multicenter Study to Evaluate Maintenance of Response, Safety and Patient Reported Outcomes in Acromegaly Patients Treated with Octreotide Capsules, and in Patients Treated with Standard of Care Parenteral Somatostatin Receptor Ligands who Previously Tolerated and Demonstrated a Biochemical Control on Both Treatments.""	Kautzky-Willer Alexandra	Innere Medizin III_716
FA716B1501	THE ROLE OF LEPTIN IN REGULATING HEPATIC LIPID METABOLISM IN LIPODYSTROPHY	Scherer Thomas	Innere Medizin III_716
FA716F0105	""EpiTyp-2"" Epigenetik-basierte Typ-2-Diabetes Diagnostik aus Speichel und Blut Kooperation"	Kautzky-Willer Alexandra	Innere Medizin III_716
FA716E0945	A randomized, placebo controlled, double-blind, parallel-arm feasibility (pilot) study to evaluate safety and clinical efficacy of G-PUR [®] treatment in patients with irritable bowel syndrome with diarrhea (IBS-D)	Trauner Michael	Innere Medizin III_716
FA716D1802	Registry for patients with rheumatic diseases at the intensive care unit	Unger Manuel	Innere Medizin III_716
FA716E0945	A randomized, placebo controlled, double-blind, parallel-arm feasibility (pilot) study to evaluate safety and clinical efficacy of G-PUR [®] treatment in patients with irritable bowel syndrome with diarrhea (IBS-D)	Trauner Michael	Innere Medizin III_716
FA716B1310	Evaluation of long-term complications after bariatric surgery - A questionnaire-based long-term follow-up pilot study	Krebs Michael	Innere Medizin III_716
FA716C2701	Unrestricted Scientific Grant	Eder Michael	Innere Medizin III_716

FA716C2102	Entwicklung eines spezifischen Covid19 Antikörpertests	Wahrmann Markus	Innere Medizin III_716
FA716E0973	A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence	Trauner Michael	Innere Medizin III_716
FA716E0974	A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma	Trauner Michael	Innere Medizin III_716
FA716B0315	SURROGATE BRAIN MARKERS OF NEUROLOGICAL DEFICITS IN GALACTOSEMIA	Stulnig Thomas	Innere Medizin III_716
UE71606010	Kooperationsvertrag CEMM 50% Facharztstelle	Trauner Michael	Innere Medizin III_716
FA716D0713	wissenschaftliche Bearbeitung des Themas "Primary Immunodeficiencies - Austrian Register	Scheinecker Clemens	Innere Medizin III_716
FA716D0712	Vereinbarung Research Grant	Scheinecker Clemens	Innere Medizin III_716
FA716C0912	Nachweis einer Nierentransplantatsabstoßung durch NMR-basierte Urinmetabolomics	Böhmig Georg	Innere Medizin III_716
FA716E0838	An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)"	Trauner Michael	Innere Medizin III_716
FA716E0843	AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144	Trauner Michael	Innere Medizin III_716
FA716E0831	Phase III, double-blind, placebo-controlled, multicenter study of the efficacy and safety of etrolizumab during induction and maintenance in patients with moderate to severe active ulcerative colitis who are refractory to or intolerant of TNF inhibitors	Trauner Michael	Innere Medizin III_716

FA716E0830	An open-label extension and safety monitoring study of moderate to severe	Trauner Michael	Innere Medizin III_716
FA716E0829	Phase III, randomized, multicenter double-blind, double-dummy study to evaluate the efficacy and safety of Etrolizumab compared with infliximab in patients with moderate to severe active ulcerative colitis who are naive to TNF inhibitors	Trauner Michael	Innere Medizin III_716
FA716C2601	Effect of empagliflozin on the renin-angiotensin system in patients with chronic kidney disease with and without type 2 diabetes	Hecking Manfred	Innere Medizin III_716
FA716E0971	A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease	Trauner Michael	Innere Medizin III_716
FA716D1801	Registry for patients with rheumatic diseases at the intensive care unit	Becede Manuel	Innere Medizin III_716
FA716E0972	A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis	Trauner Michael	Innere Medizin III_716
FA716C1011	"Alexion Studie ALXN1210-aHUS-311 Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naive Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS)."	Oberbauer Rainer	Innere Medizin III_716
FA716E0969	Randomized, placebo-controlled, double blind, multi-centre Phase IIb study to evaluate the efficacy and safety of HepaStem in patients with Acute on Chronic Liver Failure (ACLF) - DHELIVER" EudraCT number: 2019-003051-11	Trauner Michael	Innere Medizin III_716
FA716E0970	Kooperationsvertrag CEMM 50% Facharztstelle	Trauner Michael	Innere Medizin III_716

FA716E0968	WO41535 - A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AT HIGH RISK OF RECURRENCE AFTER SURGICAL RESECTION OR ABLATION	Trauner Michael	Innere Medizin III_716
UE71606009	Personalkostenförderung	Kautzky-Willer Alexandra	Innere Medizin III_716
FA716E0967	Randomized, placebo-controlled, double blind, multi-centre Phase IIb study to evaluate the efficacy and safety of HepaStem in patients with Acute on Chronic Liver Failure (ACLF) - DHELIVER	Trauner Michael	Innere Medizin III_716
FA716B0616	A randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of individually titrated oral doses of runcaciguat in subjects with clinical diagnosis of chronic kidney disease with diabetes and/or hypertension and at least one cardiovascular comorbidity“, CONCORD Study und der Bayer-Nummer BAY 1101042	Kautzky-Willer Alexandra	Innere Medizin III_716
FA716E0963	A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation	Trauner Michael	Innere Medizin III_716
FA716E0966	A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis	Trauner Michael	Innere Medizin III_716
FA716E0964	Unverblindete Langzeitsicherheitsstudie von Spesolimab bei der Behandlung von Patienten mit fistelbildendem Morbus Crohn die vorhergehende Spesolimab Studien abgeschlossen haben	Trauner Michael	Innere Medizin III_716
FA716E0965	A phase 2b, open-label, efficacy and safety study of ABX464 as maintenance therapy in patients with moderate to severe Ulcerative Colitis.	Trauner Michael	Innere Medizin III_716

	A randomized, placebo controlled, double-blind, parallel-arm feasibility (pilot) study to evaluate safety and clinical efficacy of G-PUR® treatment in patients with irritable bowel syndrome with diarrhea (IBS-D)	Trauner Michael	Innere Medizin III_716
FA716B1901	Tracking Nutrient Metabolism and Cellular Partitioning by Multimodal Molecular Imaging - WWTF Life Sciences Call 2019	Krssak Martin	Innere Medizin III_716
FA716B0615	The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)	Kautzky-Willer Alexandra	Innere Medizin III_716
FA716E0962	A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease	Trauner Michael	Innere Medizin III_716
FA716B0614	„Eine randomisierte Phase-II-Studie mit Parallelgruppen zur Dosisfindung von über einen Zeitraum von 16 Wochen subkutan verabreichtem BI 456906 im Vergleich mit Plazebo und Semaglutid (open-label) bei Patienten mit Typ-2-Diabetes mellitus.“	Kautzky-Willer Alexandra	Innere Medizin III_716
FA716B0613	A multinational, randomized, double-blind, placebocontrolled study to assess the efficacy, pharmacodynamics, pharmacokinetics, and safety of venglustat in late-onset GM2, EFC 15299 - AMETHIST mit der Substanz GZ402671 - VENGLUSTAT	Kautzky-Willer Alexandra	Innere Medizin III_716
FA716C0913	A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients	Böhmig Georg	Innere Medizin III_716
FA716D0608	A 52-week, multicenter study to assess the time course of response to sekuniumab on joint inflammation using Power Doppler ultrasonography in patients with active psoriatic arthritis	Machold Klaus	Innere Medizin III_716

FA716D0805	A randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects with New-Onset Polymyalgia Rheumatica (PMR-SPARE)	Aletaha Daniel	Innere Medizin III_716
FA716B1801	Datenauswertung	Winhofer-Stöckl Yvonne	Innere Medizin III_716
FA716D0244	Approved Grant for CONSENSUS STATEMENT ON THE USE OF JANUS KINASE INHIBITORS IN RHEUMATOLOGY	Smolen Josef	Innere Medizin III_716
FA716B1309	Collaborative Research Agreement - Verhältnis zwischen Insulinempfindlichkeit und Risiko für Herz-Kreislaufkrankungen	Krebs Michael	Innere Medizin III_716
	...	Oberbauer Rainer	Innere Medizin III_716
FA716D1601	Grundlagenprojekt zur epigenetischen Regulation von IL-1b in der experimentellen Arthritis durch miR-146a	Blüml Stephan	Innere Medizin III_716
FA716C0911	Sicherheit, Verträglichkeit und Aktivität des Anti-IL-6-Antikörpers Clazakizumab bei späterer Antikörper-mediierter Abstoßung nach Nierentransplantation	Böhmig Georg	Innere Medizin III_716
	test	Soare Dan Valentin	IT-Systems & Communications_230
UE78106012	Neuropsychologische und sozioemotionale Aspekte von Neurofibromatose differenzierter erforschen	Pletschko Thomas	Kinder- und Jugendheilkunde_781
UE78106016	CDG-Internship	Kratochwill Klaus	Kinder- und Jugendheilkunde_781
	INNODIA: Ein innovativer Zugang zum Verständnis und Heilung von Typ 1 Diabetes	Rami-Merhar Birgit	Kinder- und Jugendheilkunde_781
FA781G0206	MRX-502: Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC) - MARCH-PFIC	Huber Wolf-Dietrich	Kinder- und Jugendheilkunde_781
FA781F0210	Early allergen-specific immunotherapy to prevent the development of allergy	Szépfolusi Zsolt	Kinder- und Jugendheilkunde_781
FA781B2901	MAIA-Entlassungsplattform	Bibl Katharina	Kinder- und Jugendheilkunde_781
FA781G0205	MRX-503: An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC)	Huber Wolf-Dietrich	Kinder- und Jugendheilkunde_781

FA781F0208	Eine multizentrische, randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Bewertung der Wirksamkeit und Sicherheit von Lenabasum bei Cystischer Fibrose	Szépfalusi Zsolt	Kinder- und Jugendheilkunde_781
FA781B1503	EU H2020 Effect of Allopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome (ALBINO-trial)	Klebermaß-Schrehof Katrin	Kinder- und Jugendheilkunde_781
FA781D0607	The dynamic interplay between bleeding phenotype and baselone factor level in moderate and mild hemophilia A and B	Male-Dressler Christoph	Kinder- und Jugendheilkunde_781
FA781B1403	Repositioning to tackle COVID-19	Förster-Waldl Elisabeth	Kinder- und Jugendheilkunde_781
FA781B2705	Augmented/Mixed Reality Intubation	Wagner Michael	Kinder- und Jugendheilkunde_781
FA781B0807	Europäische Wachstumsforen Datenbank zu Increlex	Häusler Gabriele	Kinder- und Jugendheilkunde_781
FA781G0301	Development of Transition Programme for adolescent patients with juvenile idiopathic arthritis	Seferagic Sanja	Kinder- und Jugendheilkunde_781
FA781F0605	Clinical Open label Phase II Trial rhLaman Chiesi	Konstantopoulou Vassiliki	Kinder- und Jugendheilkunde_781
UE78106014	EOPD - Mobiler Psychologischer Dienst	Leiss Ulrike	Kinder- und Jugendheilkunde_781
FA781F1102	Modellierung der Mechanismen von Corpus Callosum assoziierten Erkrankung in zerebralen Organoiden	Seidl Rainer	Kinder- und Jugendheilkunde_781
FA781B2704	3D RETENTION: 3D-pRinted pEdiaTric and nEoNatal models for simulaTion and skills acquisitiON - a pilot project	Wagner Michael	Kinder- und Jugendheilkunde_781
FA781F1501	Die Entdeckung des Vitamin B12 Mangels im Neugeborenenenscreening - ein Vorteil ?	Göschl Bernadette	Kinder- und Jugendheilkunde_781
FA781F0112	Forschungsunterstützung Novo Nordisk	Häusler Gabriele	Kinder- und Jugendheilkunde_781
FA781F0903	EU H2020 KidsAP	Rami-Merhar Birgit	Kinder- und Jugendheilkunde_781
UE78106016	CDG-Internship	Kratochwill Klaus	Kinder- und Jugendheilkunde_781
FA781D0601	Joint-health Outcome Scoring: Exploration in Patients with Hemophilia in Austria	Male-Dressler Christoph	Kinder- und Jugendheilkunde_781
FA781D0442	Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Previously Untreated Patients with Haemophilia A	Male-Dressler Christoph	Kinder- und Jugendheilkunde_781

FA781D0439	A phase III, prospective, multicenter, uncontrolled, open-label clinical study to determine the efficacy, safety and tolerability of rVWF with or without ADVATE in the treatment and control of bleeding episodes, the efficacy and safety of rVWF in elective and emergency surgeries, and the pharmacokinetics (PK) of rVWF in children diagnosed with severe Von Willebrand Disease	Male-Dressler Christoph	Kinder- und Jugendheilkunde_781
FA781D0438	Safety and Efficacy of nonacog beta pegol (N9-GP) in Previously Untreated Patients with Hemophilia B	Male-Dressler Christoph	Kinder- und Jugendheilkunde_781
FA781D0435	Prospective Multi-Center Evaluation of the Duration of Therapy for Thrombosis in Children - KIDS-DOTT	Male-Dressler Christoph	Kinder- und Jugendheilkunde_781
FA781D0427	Open label, single arm safety prospective study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years	Male-Dressler Christoph	Kinder- und Jugendheilkunde_781
FA781D0425	A multi-center, phase III, non-controlled, open-label trial to evaluate the pharmacokinetics, safety and efficacy of BAY 94-9027 for prophylaxis and treatment of bleeding in previously treated children (age < 12 years) with severe hemophilia A	Male-Dressler Christoph	Kinder- und Jugendheilkunde_781
FA781D0424	A multicentre Phase III uncontrolled, open-label trial to evaluate the safety and efficacy of BAY 81-8973 in children with severe Hemophilia A under prophylaxis treatment	Male-Dressler Christoph	Kinder- und Jugendheilkunde_781
FA781F1003	Open-label, Single-Arm, Multicenter Study to Evaluate the Safety, Tolerability and Activity of Evolocumab for LDL-C Reduction, as Add-On to Diet and Lipid-Lowering Therapy, in Pediatric Subjects From 10 to 17 Years of Age With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH)	Greber-Platzer Susanne	Kinder- und Jugendheilkunde_781
FA781G0112	IMPROVE – PD: Identification and Management of Patients at Risk – Outcome and Vascular Events in Peritoneal Dialysis	Aufricht Christoph	Kinder- und Jugendheilkunde_781

FA781B1116	RAINBOW extension study: an extension study to evaluate the long term efficacy and safety of RAnibizumab compared with laser therapy for the treatment of INfants BOrn prematurely With retinopathy of prematurity	Berger Angelika	Kinder- und Jugendheilkunde_781
FA781F1008	A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Label Treatment Period to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents with Heterozygous Familial Hypercholesterinemia	Greber-Platzer Susanne	Kinder- und Jugendheilkunde_781
FA781B1115	An extension study to evaluate the long-term outcomes of subjects who received treatment for retinopathy of prematurity in Study 20090	Berger Angelika	Kinder- und Jugendheilkunde_781
FA781D0420	A Phase 3b Open-label, Multicenter, Safety and Efficacy Extension Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects with Hemophilia B	Male-Dressler Christoph	Kinder- und Jugendheilkunde_781
UE78106007	OKids	Greber-Platzer Susanne	Kinder- und Jugendheilkunde_781
UE78106015	NF Forscherwerkstatt	Pletschko Thomas	Kinder- und Jugendheilkunde_781
FA781B2201	Mein Logbuch - Ich kenne mich aus!	Weiler-Wichtl Liesa	Kinder- und Jugendheilkunde_781
FA781G0404	An Observational Registry Study To Evaluate The Use And Safety Of Cinacalcet Among Paediatric Patients With Secondary Hyperparathyroidism	Arbeiter Klaus	Kinder- und Jugendheilkunde_781
FA781B2703	SURV1VE-Trial (Sustained inflation and chest compression versus 3:1 chest compression to ventilation ratio during cardiopulmonary resuscitation of asphyxiated newborns – a cluster randomized controlled trial)	Wagner Michael	Kinder- und Jugendheilkunde_781
FA781B1113	Open-label, randomized, two-arm, controlled study to assess the efficacy, safety, and tolerability of intravitreal (IVT) aflibercept compared to laser photocoagulation in patients with retinopathy of prematurity (ROP)	Berger Angelika	Kinder- und Jugendheilkunde_781
FA781B2502	Aktualisierung der S3 Leitlinie Psychosoziale Versorgung in der pädiatrischen Onkologie	Leiss Ulrike	Kinder- und Jugendheilkunde_781

	A phase 3b, prospective open-label, uncontrolled, multicenter study on long-term safety and efficacy of rVWF in pediatric and adult subjects with severe von Willebrand disease (VWD)	Male-Dressler Christoph	Kinder- und Jugendheilkunde_781
FA781F1401	A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents aged 6 to 17 Years with Attention-deficit/Hyperactivity Disorder	Klier Claudia	Kinder- und Jugendheilkunde_781
FA765A0101	"In2Vis, Interactive Information Visualization: Exploring and Supporting Human Reasoning Processes Proj.Nr.: CI038"	Ohmann Susanne	Kinder- und Jugendpsychiatrie_765
	Eine randomisierte, doppelblinde, Placebo kontrollierte Phase I Studie (erstmalig am Menschen) mit adaptiven Design und ansteigenden Einzeldosierungen gefolgt von Kohorten mit ansteigender Mehrfachdosierung zur Evaluierung der Sicherheit, Verträglichkeit und Pharmakokinetik von REM0046127 an gesunden Probanden.	Wolzt Michael	Klinische Pharmakologie_729
FA729A0158	A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (disease caused by infection with severe acute respiratory syndrome coronavirus-2)	Jilma Bernd	Klinische Pharmakologie_729
FA729A0148	Safety, Tolerability and Efficacy of anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection after Kidney Transplantation – a Pilot Trial	Jilma Bernd	Klinische Pharmakologie_729
FA729A0262	Follow-up study for patients having received fluPHPVE6E7 in clinical studies	Wolzt Michael	Klinische Pharmakologie_729
FA729A1028	FULL Plasma, ELF and intraperitoneal pharmacokinetics of ceftazidime-avibactam in critically ill and peritoneal dialysis patients	Zeitlinger Markus	Klinische Pharmakologie_729

FA729A0253	A phase I, (first in human) randomized, double-blind, placebo-controlled single- and multiple-ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of MW150 in healthy young subjects and one elderly cohort	Wolzt Michael	Klinische Pharmakologie_729
FA729A0254	A randomized, placebo-controlled, double-blind study to evaluate the effect of G-PUR on enteral lead isotope 204Pb-absorption	Wolzt Michael	Klinische Pharmakologie_729
FA729A0255	A randomized, parallel arm, placebo-controlled, double-blind study to evaluate safety and clinical efficacy of G-PUR treatment in patients with irritable bowel syndrome with diarrhea (IBS-D)g	Wolzt Michael	Klinische Pharmakologie_729
FA729A0728	A phase I safety and tolerability study of PP-001 eye drops in healthy adult volunteers	Garhöfer Gerhard	Klinische Pharmakologie_729
FA729A1041	Efficacy of solnate to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS	Zeitlinger Markus	Klinische Pharmakologie_729
FA729A0155	A single/multiple ascending dose phase 1 study of the safety, tolerability and pharmacologic activity of BT200 in normal human volunteers	Jilma Bernd	Klinische Pharmakologie_729
FA729A0139	Phase 2 clinical trial of the BioMed rTSST-1 variant vaccine in healthy adults	Jilma Bernd	Klinische Pharmakologie_729
FA729A0148	Safety, Tolerability and Efficacy of anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection after Kidney Transplantation – a Pilot Trial	Jilma Bernd	Klinische Pharmakologie_729
FA729A1040	A multi-center, double-blinded and open-label extension study to evaluate the efficacy and safety of ligelizumab as retreatment, self-administered therapy and monotherapy in Chronic Spontaneous Urticaria patients who completed studies CQGE031C2302, CQGE031C2303, CQGE031C2202 or CQGE031C1301	Zeitlinger Markus	Klinische Pharmakologie_729
FA729A0735	A Phase II/III, Randomized, Double-Masked, Vehicle-Controlled, Efficacy, Safety and Tolerability Study of Chlorprocaine 3% Gel Eye Drops in Healthy Volunteers	Garhöfer Gerhard	Klinische Pharmakologie_729

FA729A0261	A prospective, randomized, open-label, controlled, exploratory trial to investigate the safety and tolerability of topically administered VZ in healthy male subjects with artificial dermal wounds	Wolzt Michael	Klinische Pharmakologie_729
FA729A0260	Randomised, double-blind, placebo-controlled phase 1 dose-escalation study of FluBHPVE6E7 in HPV-16 infected women with normal cytology or low-grade cervical intraepithelial neoplasia	Wolzt Michael	Klinische Pharmakologie_729
	Randomised, double-blind, placebo-controlled phase 1 dose-escalation study of FluBHPVE6E7 in HPV-16 infected women with normal cytology or low-grade cervical intraepithelial neoplasia	Wolzt Michael	Klinische Pharmakologie_729
FA729A0157	IMMUNOGENICITY AND SAFETY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME DISEASE, IN HEALTHY ADULTS AGED 18 TO 70 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY	Jilma Bernd	Klinische Pharmakologie_729
FA729A1032	Model Development	Zeitlinger Markus	Klinische Pharmakologie_729
FA794C0403	Vergleich einer neuartigen chemischen Reinigung gegenüber der herkömmlichen manuellen Reinigung in der Reinigungsphase der Aufbereitung von Endoskopen	Diab-El Schahawi Magda	Krankenhaushygiene und Infektionskontrolle_794
FA793B0113	Evaluation des neuen Sensitive Yeast One Systems zur Bestimmung der antifungalen Empfindlichkeit von Sprosspilzen	Willinger Birgit	Labormedizin_793
FA793B0111	Influence of Chlorhexidine on C. albicans and C. glabrata upon long term exposure	Willinger Birgit	Labormedizin_793
FA793B0112	Sammlung und Analyse von Daten antifungaler Resistenzen von Hefepilzen aus klinisch relevantem Untersuchungsmaterial 2020	Willinger Birgit	Labormedizin_793
FA793C0201	Leistungsbewertung des CE/IVD zertifizierten NeuMoDx Systems zur Detektion und Quantifizierung von Epstein-Barr-Virus (EBV) und Cytomegalovirus (CMV) DNA; Performance evaluation of the CE/IVD-certified NeuMoDx System for detection and quantification of Epstein-Barr-Virus (EBV) and Cytomegalovirus (CMV) DNA	Straßl Robert Paul	Labormedizin_793

FA793A0804	Modulation von oxidativem Stress bei Stoffwechselerkrankungen: ein neuer therapeutischer Ansatz	Binder Christoph	Labormedizin_793
FA793A2202	Deciphering the molecular and functional heterogeneity of group 2 innate lymphoid cells in cancer	Wagner Erwin Friedrich	Labormedizin_793
FA793A0336	cobas t711-RD004741	Quehenberger Peter	Labormedizin_793
FA793B0310	Evaluation of SeptiReal, MycoReal and PanReal pathogen detection PCR kits developed by Ingenetix GmbH using existing DNA-extracts of patient samples	Makrithathis Athanasios	Labormedizin_793
FA793A0333	Cobas t711 - F8	Quehenberger Peter	Labormedizin_793
FA793A1704	Harmonization of Next-Generation Sequencing for myeloid neoplasias in Austria	Esterbauer Harald	Labormedizin_793
FA793A1703	CSL Behring - Diagnostische Analyse bei Alpha-1-Antitrypsin-Mangel	Esterbauer Harald	Labormedizin_793
FA793A1701	CSL Behring - Genetische Analyse von pseudonymisierten Studienproben bei Hämophilie (F8, F9)	Esterbauer Harald	Labormedizin_793
FA793A2001	Development of therapeutics targeting mutant CALR	Kralovics Robert	Labormedizin_793
FA793B0105	In vitro efficacy of octenidine against multidrug-resistant Candida spp.	Willinger Birgit	Labormedizin_793
FA793A0335	Assay Performance Evaluation on cobas t 711 analyzer – Factor Assays	Quehenberger Peter	Labormedizin_793
FA793A1902	“A randomized, placebo controlled, double-blind, parallel-arm feasibility (pilot) study to evaluate safety and clinical efficacy of G-PUR® treatment in patients with irritable bowel syndrome with diarrhea (IBS-D)	Haslacher Helmuth	Labormedizin_793
FA793A2201	Innovative strategies for cancer prevention with focus on sex hormone signaling and chronic inflammation	Wagner Erwin Friedrich	Labormedizin_793
FA793A1009	Targeting TGF superfamily using Acceleron Pharma compounds in the Fra-2 transgenic mouse model of multiorgan fibrosis	Wagner Erwin Friedrich	Labormedizin_793
FA793B0110	Evaluation der automatisierten Durchführung, Ablesung und Interpretation der Agardiffusion mittels DiskA	Willinger Birgit	Labormedizin_793
FA793A0328	071301 rVWF in prophylaxis	Quehenberger Peter	Labormedizin_793
FA793A0328	071301 rVWF in prophylaxis	Quehenberger Peter	Labormedizin_793
FA793A0333	Cobas t711 - F8	Quehenberger Peter	Labormedizin_793

FA793A0318	Hemophilia Inhibitor PUP study	Quehenberger Peter	Labormedizin_793
FA793C0101	Vergleich von molekularen Assays für die Schnelldetektion von Influenza A, Influenza B und Respiratorisches Synzytial-Virus	Mayer Florian	Labormedizin_793
FA793B0105	In vitro efficacy of octenidine against multidrug-resistant Candida spp.	Willinger Birgit	Labormedizin_793
FA616A1001	Elucidating the mechanics of mitotic chromosome assembly by light-, electron-, and atomic force microscopy	Otsuka Shotaro	Medizinische Biochemie_305
FA618A0702	SFB 80 RNAdeco: decorating RNA for a purpose/ Teilprojekt 10: Enzymologie, Substrate und Funktion terminaler RNA-Modifikationen	Martinez Javier Augusto	Medizinische Biochemie_305
FA616A0901	Regulationsmechanismen von Stressgranule Bildung und Auflösung	Karagöz Gülsün Elif	Medizinische Biochemie_305
FA616A0403	Phasenseparierte Lipidoplets als Zentrum für nukleare Proteinqualitätskontrolle	Köhler Alwin	Medizinische Biochemie_305
FA618A0701	Diamond-Blackfan-Anemia	Martinez Javier Augusto	Medizinische Biochemie_305
FA605A0406	EU OCTchip H2020-ICT-2015	Drexler Wolfgang	Medizinische Physik und Biomedizinische Technik_340
FA605A2801	Verbesserung der Bewegungskorrektur in der MRT	Zaitsev Maxim	Medizinische Physik und Biomedizinische Technik_340
UE60506007	Future SS-OCT technologies, High speed OCT, functional OCT and Synthetic aperture imaging OCT	Drexler Wolfgang	Medizinische Physik und Biomedizinische Technik_340
FA605A1502	Entwicklung einer flexiblen 23-Kanal Hochfrequenzspule für Siemens 3T Magnetresonanztomografen	Laistler Elmar	Medizinische Physik und Biomedizinische Technik_340
FA605A0411	Rahmenvertrag Alsix	Drexler Wolfgang	Medizinische Physik und Biomedizinische Technik_340
FA605A1801	EU H2020 FBI Multimodal, Functional Bio-Photonic Imaging	Leitgeb Rainer	Medizinische Physik und Biomedizinische Technik_340
FA605A0409	EU H2020 Hybrid optical and optoacoustic endoscope for esophageal tracking	Drexler Wolfgang	Medizinische Physik und Biomedizinische Technik_340
FA605A1004	Teilautomatisierte Testung von Biosignal Verstärkern	Bijak Manfred	Medizinische Physik und Biomedizinische Technik_340
FA605A0704	Chronische Elektrostimulation zur Therapie der Altersstimme	Lanmüller Hermann	Medizinische Physik und Biomedizinische Technik_340
FA605A2801	Verbesserung der Bewegungskorrektur in der MRT	Zaitsev Maxim	Medizinische Physik und Biomedizinische Technik_340
FA605A0907	Ventilator for Covid-19	Rafolt Dietmar	Medizinische Physik und Biomedizinische Technik_340
FA605A0906	Innovationsscheck: Additive Fertigung und messtechnische Unterstützung für einen HNO Teststand	Rafolt Dietmar	Medizinische Physik und Biomedizinische Technik_340

FA605A2701	Zielregionen für TMS	Tik Martin	Medizinische Physik und Biomedizinische Technik_340
FA605A1806	Vermessung von Tablettenschichten mit hochauflösenden OCT Systemen	Leitgeb Rainer	Medizinische Physik und Biomedizinische Technik_340
FA605A2204	Mammographiephantom	Figl Michael	Medizinische Physik und Biomedizinische Technik_340
FA605A1402	Multi-modal, multi-scale retinal imaging	Pircher Michael	Medizinische Physik und Biomedizinische Technik_340
FA605A1805	Photonics for Healthcare: multiscale cancer diagnosis and Therapy	Leitgeb Rainer	Medizinische Physik und Biomedizinische Technik_340
UE60506007	Future SS-OCT technologies, High speed OCT, functional OCT and Synthetic aperture imaging OCT	Drexler Wolfgang	Medizinische Physik und Biomedizinische Technik_340
FA605A1802	EU H2020 Multi-modal Optical Diagnostics for Ocular and Neurodegenerative Disease	Leitgeb Rainer	Medizinische Physik und Biomedizinische Technik_340
FA605A2001	Entwicklung und Evaluierung des 3D Qualitätssicherungsphantoms für Tomosynthese	Hummel Johann	Medizinische Physik und Biomedizinische Technik_340
FA605A2101	Improving Clinical PET Imaging for non-optimal positron emitters	Beyer Thomas	Medizinische Physik und Biomedizinische Technik_340
FA605A2203	Konturvermessung	Figl Michael	Medizinische Physik und Biomedizinische Technik_340
FA605A2601	Link Skin Morphology and Vasculature with Diseases using Optical Imaging	Liu Mengyang	Medizinische Physik und Biomedizinische Technik_340
FA605A2602	Switchable magneto-plasmonic contrast agents and molecular imaging technologies	Liu Mengyang	Medizinische Physik und Biomedizinische Technik_340
FA605A2001	Entwicklung und Evaluierung des 3D Qualitätssicherungsphantoms für Tomosynthese	Hummel Johann	Medizinische Physik und Biomedizinische Technik_340
FA605A0405	CMOS Herstellungsverfahren für Siliziumnitridwellenleiter zur Miniaturisierung von optischen Kohärenztomographiegeräten	Drexler Wolfgang	Medizinische Physik und Biomedizinische Technik_340
FA605A0408	"3D photoakustische Bildgebungssonde für die intraoperative Diagnostik Bridge 1"	Drexler Wolfgang	Medizinische Physik und Biomedizinische Technik_340
FA605A2302	Pumpe für ECCO2R - Anteil BMT	Schima Heinrich	Medizinische Physik und Biomedizinische Technik_340
FA605A1904	Ink-based hybrid multimaterial fabrication of next generation implants	Moscato Francesco	Medizinische Physik und Biomedizinische Technik_340
UE60506008	Kooperation Hanusch Krankenhaus VIROS	Leitgeb Rainer	Medizinische Physik und Biomedizinische Technik_340
FA605A0406	EU OCTchip H2020-ICT-2015	Drexler Wolfgang	Medizinische Physik und Biomedizinische Technik_340
FA605A1503	Magnetic resonance coils	Laistler Elmar	Medizinische Physik und Biomedizinische Technik_340
FA660A1204	Optimal gender-specific treatment paths on healthcare multiplex networks	Klimek Peter	Medizinische Statistik, Informatik und Intelligente Systeme_303

FA660A1401	"EU Ubiquitous Pharmacogenomics (U-PGx): Making actionable pharmacogenomic data and effective treatment optimization accessible to every European citizen – U-PGx"	Samwald Matthias	Medizinische Statistik, Informatik und Intelligente Systeme_303
UE63206001	Verein ASDI - Zertifizierung von Intensivstationen	Posch Martin	Medizinische Statistik, Informatik und Intelligente Systeme_303
UE63206001	Verein ASDI - Zertifizierung von Intensivstationen	Posch Martin	Medizinische Statistik, Informatik und Intelligente Systeme_303
FA632A0507	Planung und Auswertung der Studie "Beobachtung von Sicca-PatientInnen, die mit HYLO-PROTECT versus HYLO-FRESH behandelt werden" (HYPRODA)	Ristl Robin	Medizinische Statistik, Informatik und Intelligente Systeme_303
FA602A0116	H2O Health Outcomes Observatory	Stamm Tanja	Medizinische Statistik, Informatik und Intelligente Systeme_303
FA660A1801	Evolutionary games and population dynamics: from theory to applications	Hanel Rudolf	Medizinische Statistik, Informatik und Intelligente Systeme_303
FA660A1702	An observer partially-blinded, lesion-randomized, intra-patient controlled, 3-arm, monocentric Pilot Phase I study to assess safety and efficacy of a localized, laser-assisted topical administration of Etanercept (Enbrel®) in patients with plaque-type psoriasis (TopPso-2018)	Mittlböck Martina	Medizinische Statistik, Informatik und Intelligente Systeme_303
FA602A0117	EUROSTARS-2 CoD13: 114332 RB4.0 - Develop a digital service to improve care and quality of life in patients with Rheumatoid Arthritis	Stamm Tanja	Medizinische Statistik, Informatik und Intelligente Systeme_303
	Evolutionary games and population dynamics: from theory to applications	Hanel Rudolf	Medizinische Statistik, Informatik und Intelligente Systeme_303
FA632A0505	Nutrition Day	Ristl Robin	Medizinische Statistik, Informatik und Intelligente Systeme_303
FA632A0506	Praktikum Statistik	Ristl Robin	Medizinische Statistik, Informatik und Intelligente Systeme_303
FA602A0115	Selbstberichtetes COVID-19 Symptomtracking mit Hilfe einer anonymisierten On-line Umfrage	Stamm Tanja	Medizinische Statistik, Informatik und Intelligente Systeme_303
FA632A0402	Praktikum Statistik	Frommlet Florian	Medizinische Statistik, Informatik und Intelligente Systeme_303
FA602A0114	The mental Health eXperience; Indication - iNtervention - eXperience	Stamm Tanja	Medizinische Statistik, Informatik und Intelligente Systeme_303
FA742A0801	First-In-Man Performance and Safety Evaluation of the CARLO® (Cold Ablation Robot-guided Laser Osteotome)	Holzinger Daniel	Mund-, Kiefer- und Gesichtschirurgie_742
FA736A0501	Reresearch in 5-ALA Fluorescence in Neurosurgery	Widhalm Georg	Neurochirurgie_736

FA736A0501	Reresearch in 5-ALA Fluorescence in Neurosurgery	Widhalm Georg	Neurochirurgie_736
FA796A0112	Durchführungen von Leistungen im Rahmen der Umsetzung des Nationalen Aktionsplans für seltene Erkrankungen - Nationales Büro zur Umsetzung und Weiterentwicklung des NAP.se	Voigtlaender Till	Neurologie_761
FA761A1125	The effect of Cladribine on iron rims around lesions, lesion expansion, brain atrophy and disease progression in multiple sclerosis patients - an observational exploratory study	Berger Thomas	Neurologie_761
FA761A1124	A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient reported outcomes in patients with relapsing multiple sclerosis transitionin from dimethyl fumerate or fingolimod therapy	Berger Thomas	Neurologie_761
FA761A1123	1.) Serum Neurofilament light chains as a marker for neurological manifestation in Fabry Disease 2.) Neuroinflammation in Fabry Disease and Gaucher Disease: histopathological examination in human brains	Berger Thomas	Neurologie_761
UE76106004	Translational morphology in Neuroscience	Berger Thomas	Neurologie_761
FA796A0502	Klonale Komplexität des Glioblastoms	Wöhrrer Adelheid	Neurologie_761
FA761A1122	Prospective observational study of Fremanezumab (Ajovy TM) effectiveness in chronic and episodic migraine patients in clinical routine	Berger Thomas	Neurologie_761
FA761A1121	Multicenter, randomized, placebo-controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY2433334 in patients following an acute noncardioembolic ischemic stroke PACIFIC STROKE	Berger Thomas	Neurologie_761
FA796A0501	Grantagreement Abbvie - ABTR	Wöhrrer Adelheid	Neurologie_761
FA761A1120	A Phase 3, external placebo-controlled, open-label, multicenter study to evaluate the efficacy and safety of Ravulizumab in adult patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)	Berger Thomas	Neurologie_761
UE76106003	Biomarkers in MS	Berger Thomas	Neurologie_761

FA796A0203	Weiterführung des Österr. Referenzzentrums zur Erfassung und Dokumentation menschlicher Prionen- Krankheiten im Jahr 2004	Gelpi Mantius Ellen	Neurologie_761
FA761A1119	Effects of oral Levosimedan (OMD-109) on respiratory function in patients with ALS: open-label extension for patients completing study 3119002	Berger Thomas	Neurologie_761
FA761A1118	A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of Ravulizumab in complement-inhibitor-Naive adult patients with generalized Myasthenia gravis	Berger Thomas	Neurologie_761
FA796A0112	Durchführungen von Leistungen im Rahmen der Umsetzung des Nationalen Aktionsplans für seltene Erkrankungen - Nationales Büro zur Umsetzung und Weiterentwicklung des NAP.se	Voigtlaender Till	Neurologie_761
FA796A0501	Grantagreement Abbvie - ABTR	Wöhrrer Adelheid	Neurologie_761
FA761A1109	A phase 3, randomised, rater-blinded, multi-centre study to evaluate the efficacy and safety of WTX101 administered for 48 weeks versus standard of care in Wilson Disease subjects aged 18 and older with an extension phase of up to 60 months	Berger Thomas	Neurologie-Klinik_761
FA761A0156	A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis"	Berger Thomas	Neurologie-Klinik_761
FA761A1102	Non-interventional study on Edoxaban treatment in routine clinical practice for patients with non valvular atrial fibrillation	Berger Thomas	Neurologie-Klinik_761
FA761A1104	Differentialdiagnose bei Morbus Fabry und Multiple Sklerose durch kraniale MRT	Berger Thomas	Neurologie-Klinik_761

FA761A0176	GOAL-Gilenya (Fingolimod) Outcome in treatment sAtisfaction and quality of Life) A non-interventional, prospective, multicenter, observational study assessing quality of life, treatment satisfaction and employment status of an Austrian patient population with relapsing remitting multiple sclerosis (RRMS) under Gilenya (fingolimod) treatment.	Berger Thomas	Neurologie-Klinik_761
FA761A1106	Die Fähigkeit zur Erkennung und zum Verständnis von Metaphern	Berger Thomas	Neurologie-Klinik_761
FA728A1301	Verbesserung der Workflows im Bereich Diagnose und Behandlung von Patienten mit Thoraxschmerzen	Roth Dominik	Notfallmedizin_728
FA728A1401	The effects of Cerebrolysin on neuronal damage and long-time recovery in a ventricular fibrillation Cardiac Arrest Model in the rat.	Weihls Wolfgang	Notfallmedizin_728
FA728A0605	COOL-AMI EU PIVOTAL TRIAL: A MULTICENTER, PROSPECTIVE, RANDOMIZED-CONTROLLED TRIAL TO ASSESS THE SAFETY AND EFFECTIVENESS OF COOLING AS AN ADJUNCTIVE THERAPY TO PERCUTANEOUS INTERVENTION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION	Holzer Michael	Notfallmedizin_728
FA728A0605	COOL-AMI EU PIVOTAL TRIAL: A MULTICENTER, PROSPECTIVE, RANDOMIZED-CONTROLLED TRIAL TO ASSESS THE SAFETY AND EFFECTIVENESS OF COOLING AS AN ADJUNCTIVE THERAPY TO PERCUTANEOUS INTERVENTION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION	Holzer Michael	Notfallmedizin_728
FA728A1201	Kardiovaskuläre Forschung und Biomarker in der Notfallmedizin "IVDR Performance Evaluation TROPT Sensitive Intermediate Precision cobas h 232 CIM RD005289"	Niederdöckl Jan	Notfallmedizin_728
FA737A1601	FFG Innovationsscheck Plus Denz BioMedical GmbH	Rothbauer Mario	Orthopädie und Unfallchirurgie_739
FA737A1902	Search for a common founder of the particular p.His108ArgTTR variant	Auer-Grumbach Michaela	Orthopädie und Unfallchirurgie_739

FA737A1901	Eine randomisierte, doppelblinde, placebokontrollierte, multizentrische Phase -3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Vutrisiran bei Patienten mit Transthyretin-Amyloidose mit Kardiomyopathie (ATTR - Amyloidose mit Kardiomyopathie)	Auer-Grumbach Michaela	Orthopädie und Unfallchirurgie_739
UE73706003	Phenotyping of osteoarthritis patients and clinical specimens	Tögel Stefan	Orthopädie und Unfallchirurgie_739
FA737A0619	Eine randomisierte, doppelblinde, Placebo kontrollierte, explorative Einzeldosis Phase IIb zur Bestimmung der klinischen Wirkungen und Sicherheit von intraartikulären Injektionen von Lopain (MTX-071) bei Patienten mit chronischen Kniegelenksschmerzen aufgrund von Osteoarthritis.	Windhager Reinhard	Orthopädie und Unfallchirurgie_739
UE73706003	Phenotyping of osteoarthritis patients and clinical specimens	Tögel Stefan	Orthopädie und Unfallchirurgie_739
FA737A1701	Functionalization of nanopatterned Ti for biomedical application	Staats Kevin	Orthopädie und Unfallchirurgie_739
FA737A1801	Einfluss der autologen Transplantatwahl und der Operationstechnik zur Rekonstruktion des vorderen Kreuzbands auf die postoperative Muskelaktivität gemessen mittels Tensiomyographie - eine prospektive, randomisierte Studie	Koller Ulrich	Orthopädie und Unfallchirurgie_739
FA737B0201	In-vivo Testung einer magnesiumbasierten, intramedullären Spannosteosynthese im Kaninchenmodell	Hajdu Stefan	Orthopädie und Unfallchirurgie_739
FA737A0621	Reference Center Agreement Medacta	Windhager Reinhard	Orthopädie und Unfallchirurgie_739
FA737A1601	FFG Innovationsscheck Plus Denz BioMedical GmbH	Rothbauer Mario	Orthopädie und Unfallchirurgie_739
FA737A0617	Educational Grant Johnson & Johnson /Teilnahme an int.Kongressen	Windhager Reinhard	Orthopädie und Unfallchirurgie_739
FA737A0619	Eine randomisierte, doppelblinde, Placebo kontrollierte, explorative Einzeldosis Phase IIb zur Bestimmung der klinischen Wirkungen und Sicherheit von intraartikulären Injektionen von Lopain (MTX-071) bei Patienten mit chronischen Kniegelenksschmerzen aufgrund von Osteoarthritis.	Windhager Reinhard	Orthopädie und Unfallchirurgie_739

FA681A0205	Systems medicine analysis of sarcoidosis by targeting mTOR in a co-clinical trial in patients and mice	Weichhart Thomas	Pathobiochemie und Genetik_306
FA681A0206	Role of Matrix Metalloproteinase-12 in a mouse model of sarcoidosis	Weichhart Thomas	Pathobiochemie und Genetik_306
FA608A0322	Nanopartikelcorona	Scheiber-Mojdehkar Barbara	Pathobiochemie und Genetik_306
	EPIK-B3: A Phase III, multicenter, randomized, doubleblind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nabpaclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation	Müllauer Leonhard	Pathologie_791
	A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer ("Studie"), IBCSG 59-19 POLAR,	Hofstetter Gerda	Pathologie_791
FA791A1141	A Phase 1b Open-label Study to Investigate the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of adults with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)	Simonitsch-Klupp Ingrid	Pathologie_791
FA791A2502	A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer, (KEYNOTE-A18 / ENGOT-cx11)	Dekan Sabine	Pathologie_791
FA791A1138	A Phase 2, Open-label, Single-arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)" ("Study") with protocol number JCAR017-FOL-001 ("Protocol");	Simonitsch-Klupp Ingrid	Pathologie_791

FA791A1140	A Phase 2/3 Randomized Study of Rituximabgemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL) with Protocol number XPORT-DLBCL-030	Simonitsch-Klupp Ingrid	Pathologie_791
FA791A3401	A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer	Comperat Eva Maria	Pathologie_791
FA791A3402	A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)	Comperat Eva Maria	Pathologie_791
FA791A1139	M15-954 - A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)	Simonitsch-Klupp Ingrid	Pathologie_791
FA791A3501	MX39795: A PHASE II, RANDOMIZED, ACTIVE-CONTROLLED, MULTI-CENTER STUDY COMPAR-ING THE EFFICACY AND SAFETY OF TARGETED THERAPY OR CANCER IMMUNOTHERAPY GUIDED BY GENOMIC PROFILING VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH CANCER OF UNKNOWN PRIMARY SITE WHO HAVE RECEIVED THREE CYCLES OF PLATINUM DOUBLET CHEMOTHERAPY	Oberndorfer Felicitas	Pathologie_791
FA791A1712	A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced Unresectable Pancreatic Cancer" the "Study"), bearing protocol number FGCL-3019-087	Stift Judith	Pathologie_791

FA791A0721	„EPIK-B3: A Phase III, multicenter, randomized, doubleblind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nabpaclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation“ - interner Studiencode CBYL719H12301	Müllauer Leonhard	Pathologie_791
FA791A1138	A Phase 2, Open-label, Single-arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (“Study”) with protocol number JCAR017-FOL-001 (“Protocol”);	Simonitsch-Klupp Ingrid	Pathologie_791
FA791A0720	PIK3CA Registry: A descriptive study of PIK3CA mutations in patients with HR+/Her2-advanced breast cancer	Müllauer Leonhard	Pathologie_791
FA791A1137	A Phase 1b Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Preliminary Efficacy of CC-99282 in Combination with Obinutuzumab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma” (“Study”) with protocol number CC-99282-CLL-001	Simonitsch-Klupp Ingrid	Pathologie_791
FA791A3403	An open-label multi-cohort Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-02)	Comperat Eva Maria	Pathologie_791
FA791A3103	A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma	Wöran Katharina	Pathologie_791

FA791A3306	ABCSG 52 / ATHENE: An open-label, two-arm, randomized, single-stage phase II study of ATezolizumab in combination with dual HER2 blockade plus epirubicin as NEOadjuvant therapy for HER2-positive early breast cancer	Hofstetter Gerda	Pathologie_791
FA791A1136	A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation"	Simonitsch-Klupp Ingrid	Pathologie_791
FA791A0303	"The Search for Biomarkers to Predict Nivolumab Response in NSCLC: Identification of Genomic Changes Zentrum Prof. Dr. Heller"	Streubel Berthold	Pathologie_791
FA791A1412	„An international, multicenter, Phase 1b/2 study of rogaratinib (BAY 1163877) in combination with atezolizumab as first-line treatment in cisplatin-ineligible patients with FGFR-positive locally advanced or metastatic urothelial carcinoma“ und der Bayer-Nummer 19131	Haitel Andrea	Pathologie_791
FA791A1430	A Phase 3, Randomized, Double-blind Trial of Nivolumab in Combination with Intravesical BCG versus Standard of Care BCG Alone in Participants with High-risk Non-muscle Invasive Bladder Cancer That Is Persistent or Recurrent After Treatment with BCG CA209-7G8	Haitel Andrea	Pathologie_791
FA791A2201	EU ALK Activation as a target of TRANslational Science (ALKATRAS): Break free from cancer	Merkel Olaf	Pathologie_791
FA791A1620	"A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL COMPARED WITH PLACEBO WITH NAB-PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE-NEGATIVE BREAST CANCER Zentrum Prof. Singer und Prof. Steger"	Bago-Horvath Zsuzsanna	Pathologie_791
FA791A0717	Charakterisierung von malignen Tumorerkrankungen mittels Foundation One Assay (F1 Testung)	Müllauer Leonhard	Pathologie_791

FA791A2703	A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷ Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET) – short title 'COMPETE study' Zentrum Prof. Haug	Mazal Peter	Pathologie_791
FA791A1423	A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations	Haitel Andrea	Pathologie_791
FA791A1007	Prospective, Randomized, Multi-Center Study to Evaluate Treatment of subjects with Occlusive Disease with a Novel Paclitaxel-Coated Angioplasty Balloon in Below-The-Knee (BTK) arteries	Kain Renate	Pathologie_791
FA791A1003	EU Relapses Prevention in chronic autoimmune disease: common mechanisms and co-morbidities	Kain Renate	Pathologie_791
FA791A1910	An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors Zentrum Prof. Zöchbauer-Müller	Geleff Silvana	Pathologie_791
FA791A2905	SHERBOC: A Double-blind, Placebo-controlled, Phase 2 trial of Seribantumab Plus Fulvestrant in Postmenopausal Women with Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Systemic Therapy Zentrum Prof. Singer	Tendl-Schulz Kristina	Pathologie_791

FA791A2102	"An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Zentrum Prof. Füreder"	Pammer Johannes	Pathologie_791
FA791A2302	"CA209-459: A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (CheckMate 459) Zentrum Prof. Sieghart"	Beer Andrea	Pathologie_791
FA791A1118	"Ro-CHOP – Phase 3 multi-center randomized study to compare efficacy and safety of romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphoma" Zentrum Prof. Staber"	Simonitsch-Klupp Ingrid	Pathologie_791
FA791A1115	"A phase I/II study of 177Lu-HH1 (Betalutin TM) radioimmunotherapie for treatment of relapsed non-Hodgkin lymphoma" Zentrum Prof. Raderer"	Simonitsch-Klupp Ingrid	Pathologie_791
FA791A3305	A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in the Treatment of High-risk, Stage II-III Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer CheckMate 7FL: CHECKpoint pathway and nivolumab clinical Trial Evaluation 7FL	Hofstetter Gerda	Pathologie_791
FA791A1135	Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy	Simonitsch-Klupp Ingrid	Pathologie_791

FA791A1020	A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)	Kain Renate	Pathologie_791
FA791A3304	A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Of Ipatasertib In Combination With Atezolizumab And Paclitaxel As A Treatment For Patients With Locally Advanced Unresectable Or Metastatic Triple-Negative Breast-Cancer	Hofstetter Gerda	Pathologie_791
FA791A2109	A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Combination with IV Pembrolizumab vs IV Pembrolizumab Monotherapy	Pammer Johannes	Pathologie_791
FA791A3303	ABCSG 52 / ATHENE: An open-label, two-arm, randomized, single-stage phase II study of ATezolizumab in combination with dual HER2 blockade plus epirubicin as NEOadjuvant therapy for HER2-positive early breast cancer	Hofstetter Gerda	Pathologie_791
FA791A1429	A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk. Protocol No. XL184-313	Haitel Andrea	Pathologie_791
FA791A3302	A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Trial of DS-8201A, an AntiHer2-Antibody DRUG CONJUGATE (ADC), VERSUS TREATMENT OF PHYSICIAN'S CHOICE FOR HER2LOW, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS	Hofstetter Gerda	Pathologie_791

FA791A3301	A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Trial of DS-8201A, an AntiHer2-Antibody DRUG CONJUGATE (ADC), VERSUS TREATMENT OF PHYSICIAN'S CHOICE FOR HER2LOW, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS	Hofstetter Gerda	Pathologie_791
FA791A2108	Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181, as Monotherapy and in Combination with Another Anti-Cancer Therapy in Subjects with Advanced Solid Tumors	Pammer Johannes	Pathologie_791
FA791A1134	"A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Ponatinib-3001"	Simonitsch-Klupp Ingrid	Pathologie_791
FA791A1006	Nationale Vernetzungsplattform für personalisierte Medizin "Plattform"	Kain Renate	Pathologie_791
FA791A3102	A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation. described in Protocol No. MGL-3196-11	Wöran Katharina	Pathologie_791
FA791A1428	CA045-009: A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible	Haitel Andrea	Pathologie_791

FA791A1711	A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AT HIGH RISK OF RECURRENCE AFTER SURGICAL RESECTION OR ABLATION	Stift Judith	Pathologie_791
FA791A1133	A PROSPECTIVE, OPEN-LABEL, MULTICENTRE PHASE-II-TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ZANUBRUTINIB (BGB-3111), A BTK INHIBITOR, PLUS TISLELIZUMAB (BGB-A317), A PD-1 INHIBITOR, FOR TREATMENT OF PATIENTS WITH RICHTER TRANSFORMATION	Simonitsch-Klupp Ingrid	Pathologie_791
FA791A2201	EU ALK Activation as a target of TRANslational Science (ALKATRAS): Break free from cancer	Merkel Olaf	Pathologie_791
FA791A1132	“A Phase Ib, open-label, randomized study to assess safety and preliminary efficacy of Tafasitamab in addition to R-CHOP or Tafasitamab plus Lenalidomide in addition to R-CHOP in patients with newly diagnosed Diffuse Large B-Cell Lymphoma – First-MIND”	Simonitsch-Klupp Ingrid	Pathologie_791
FA791A2908	A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in the Treatment of High-risk, Stage II-III Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer CheckMate 7FL: CHECKpoint pathway and nivolumab clinical Trial Evaluation 7FL	Tendl-Schulz Kristina	Pathologie_791
FA791A2803	Eine multizentrische, unverblindete Phase-I-Studie zur Untersuchung der Sicherheit, Verträglichkeit, Wirksamkeit und Pharmakokinetik von DCC-2618 bei Patienten mit fortgeschrittenen malignen Erkrankungen	Schiefer Ana-Iris	Pathologie_791

FA791A0719	A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation"	Müllauer Leonhard	Pathologie_791
FA791A1107	Non-Comparative, Two-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects after Failure of Autologous Stem Cell Transplantat (ASCT) - - Zentrum Prof. Jäger	Simonitsch-Klupp Ingrid	Pathologie_791
FA791A1121	"Phase II single-arm "window-of-opportunity" study of a combination of obinutuzumab (GA-101) and venetoclax (ABT-199) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL)" Zentrum Prof. Jäger"	Simonitsch-Klupp Ingrid	Pathologie_791
FA791A2404	"A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors. Zentrum Univ. Prof. Dr. Höller"	Kain Renate	Pathologie_791
FA791A1616	"SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment " Zentrum Prof. Singer"	Bago-Horvath Zsuzsanna	Pathologie_791

FA791A2303	"A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer" Zentrum Prof. Prager	Beer Andrea	Pathologie_791
FA791A0717	Charakterisierung von malignen Tumorerkrankungen mittels Foundation One Assay (F1 Testung)	Müllauer Leonhard	Pathologie_791
FA791A2103	A randomized Phase III study of pembrolizumab given concomitantly chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma	Pammer Johannes	Pathologie_791
FA791A1118	"Ro-CHOP – Phase 3 multi-center randomized study to compare efficacy and safety of romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphoma" Zentrum Prof. Staber"	Simonitsch-Klupp Ingrid	Pathologie_791
FA791A1115	"A phase I/II study of 177Lu-HH1 (Betalutin TM) radioimmunotherapie for treatment of relapsed non-Hodgkin lymphoma" Zentrum Prof. Raderer"	Simonitsch-Klupp Ingrid	Pathologie_791
FA791A1709	A randomized, double-blind, placebo controlled, 3-part, adaptive design, multicenter study to assess safety, tolerability and efficacy of tropifexor (LJN452) in patients with non-alcoholic steatohepatitis (NASH)	Stift Judith	Pathologie_791
FA791A2901	Monarch E: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer Zentrum Prof. Singer	Tendl-Schulz Kristina	Pathologie_791

FA791A1019	A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma (CheckMate 76K: CHECKpoint pathway and nivolumab clinical Trial Evaluation 76K)	Kain Renate	Pathologie_791
FA623A0215	Multilevel approach for development of anti-cancer and other vaccines on the basis of a mimotope platform technology	Wiedermann-Schmidt Ursula	Pathophysiologie, Infektiologie und Immunologie_370
FA623A0210	TBE vaccination in obese people: Evaluation of humoral and cellular immune responses in comparison to normal weight population	Wiedermann-Schmidt Ursula	Pathophysiologie, Infektiologie und Immunologie_370
FA623A0216	Serological and cellular analysis of patient samples from Hervaxx Clinical Trial Phase 1b and 2	Wiedermann-Schmidt Ursula	Pathophysiologie, Infektiologie und Immunologie_370
FA648A0306	Forschung zur Entwicklung von aktiven und passiven Impfstoffen basierend auf der Peptid/Carrier-Technologie zur spezifischen Therapie und Prävention von viralen Erkrankungen	Valenta Rudolf	Pathophysiologie, Infektiologie und Immunologie_370
FA624A0212	Immunomodulatory payload evaluation for oncolytic immunotherapy III	Steinberger Peter	Pathophysiologie, Infektiologie und Immunologie_370
FA648A0313	Developing effective allergen-specific immunotherapy	Valenta Rudolf	Pathophysiologie, Infektiologie und Immunologie_370
FA623A0224	A Phase 1/ Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety, Tolerability and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Younger and Older Participants (V591-001 Site number 0007)	Wiedermann-Schmidt Ursula	Pathophysiologie, Infektiologie und Immunologie_370
	P4 FIT: Perspectives for future innovation in tendon repair	Stöckl Johannes	Pathophysiologie, Infektiologie und Immunologie_370
FA644A0605	Characterization of T cell engager mediated synapse	Huppa Johannes	Pathophysiologie, Infektiologie und Immunologie_370
FA648A2101	Molecular strategies for oral tolerance against house dust mite allergy	Vrtala Susanne	Pathophysiologie, Infektiologie und Immunologie_370
FA648A0312	Development of prophylactic allergy vaccines	Valenta Rudolf	Pathophysiologie, Infektiologie und Immunologie_370
FA648A0311	Allergen-specific approaches targeting the nasal mucosa for treatment and prevention of allergy	Valenta Rudolf	Pathophysiologie, Infektiologie und Immunologie_370
FA623A0225	Adjuvanted allergen molecules for Treatment and prevention of allergy	Wiedermann-Schmidt Ursula	Pathophysiologie, Infektiologie und Immunologie_370

FA624A0402	Viral particle-based vaccines for treatment and prevention of allergy	Pickl Winfried	Pathophysiologie, Infektiologie und Immunologie_370
FA648A0309	Milchnahrung zur Allergieprävention im Säuglingsalter - Biochemische und immunologische Charakterisierung der Hipp-HA-Nahrung	Valenta Rudolf	Pathophysiologie, Infektiologie und Immunologie_370
FA648A1903	DARC (Danube Allergy Research Cluster) - Towards Cure of Allergy, Teilprojekt #03: "Towards Cure and Prevention of Birch Pollen-Related Food Allergy".	Bohle Barbara	Pathophysiologie, Infektiologie und Immunologie_370
FA648A0111	DARC (Danube Allergy Research Cluster) - Towards Cure of Allergy, Teilprojekt #07: "From molecular structures of food allergens and food matrix components towards diagnosis, treatment and prevention of food allergy."	Hoffmann-Sommergruber Karin	Pathophysiologie, Infektiologie und Immunologie_370
FA648A1709	Evaluierung des Zusammenhangs zwischen dem chronischem Erschöpfungssyndrom und Immundefizienzen mit Auswirkung auf die mukosale Barrierefunktionen	Untersmayr-Elsenhuber Eva	Pathophysiologie, Infektiologie und Immunologie_370
FA644A0509	Vienna Water Ressource Systems 2020+	Kirschner Alexander	Pathophysiologie, Infektiologie und Immunologie_370
FA648A0908	Epidemiological trends in food allergy	Ma Yan	Pathophysiologie, Infektiologie und Immunologie_370
FA644A0406	Vienna Water Ressource Systems 2020+	Sommer Regina	Pathophysiologie, Infektiologie und Immunologie_370
FA623A0223	CoV-2 Seroprävalenzstudie	Wiedermann-Schmidt Ursula	Pathophysiologie, Infektiologie und Immunologie_370
FA623A0507	Leishmaniose - Risikofeststellung für autochthone Infektionen bei Inlandseinsätzen des ÖBH	Walochnik Julia	Pathophysiologie, Infektiologie und Immunologie_370
FA623A0224	A Phase 1/ Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety, Tolerability and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Younger and Older Participants (V591-001 Site number 0007)	Wiedermann-Schmidt Ursula	Pathophysiologie, Infektiologie und Immunologie_370
FA644A0110	EU H2020 ID-Lyme	Stockinger Hannes	Pathophysiologie, Infektiologie und Immunologie_370
FA644A0109	EU H2020 FOLSMART	Stockinger Hannes	Pathophysiologie, Infektiologie und Immunologie_370
FA623A0220	INDUCTION OF HBV VIRUS NEUTRALIZING ANTIBODIES IN HEALTHY VACCINE NAIVE ADULTS AND NON-RESPONDERS AND IN PATIENTS CHRONICALLY INFECTED WITH HBV USING VVXX001	Wiedermann-Schmidt Ursula	Pathophysiologie, Infektiologie und Immunologie_370

FA648A0616	Osteoimmunology of hypoparathyroidism: a planning study	Pietschmann Peter	Pathophysiologie, Infektiologie und Immunologie_370
FA648A1901	Mal d 1-Gehalt in verschiedenen Apfelsorten	Bohle Barbara	Pathophysiologie, Infektiologie und Immunologie_370
FA644A0508	Ein quantitatives Konzept zur Untersuchung human-assoziiertes Antibiotikaresistenzen in Flüssen entlang des humanen Abwasserpfad	Kirschner Alexander	Pathophysiologie, Infektiologie und Immunologie_370
UE64806001	Immunological characterication of Carbohydrate-based polymers for biomedical applications	Untersmayr-Elsenhuber Eva	Pathophysiologie, Infektiologie und Immunologie_370
FA644A0111	Neue auf Stimuli reagierende Protein-Nanokapseln zur gezielten Wirkstofffreisetzung in der Brustkrebstherapie	Stockinger Hannes	Pathophysiologie, Infektiologie und Immunologie_370
FA648A2002	Genexpression	Schepelmann Martin	Pathophysiologie, Infektiologie und Immunologie_370
FA623A0223	CoV-2 Seroprävalenzstudie	Wiedermann-Schmidt Ursula	Pathophysiologie, Infektiologie und Immunologie_370
FA624A0211	Payload evaluation for oncolytic immunotherapy II	Steinberger Peter	Pathophysiologie, Infektiologie und Immunologie_370
FA623A0215	Multilevel approach for development of anti-cancer and other vaccines on the basis of a mimotope platform technology	Wiedermann-Schmidt Ursula	Pathophysiologie, Infektiologie und Immunologie_370
FA648A1021	Placental Macrophage	Ellinger Isabella	Pathophysiologie, Infektiologie und Immunologie_370
FA623A0222	Observer blinded, randomized trial to evaluate safety and immunogenicity of a novel vaccine formulation MV-ZIKA-RSP	Wiedermann-Schmidt Ursula	Pathophysiologie, Infektiologie und Immunologie_370
FA648A0306	Forschung zur Entwicklung von aktiven und passiven Impfstoffen basierend auf der Peptid/Carrier-Technologie zur spezifischen Therapie und Prävention von viralen Erkrankungen	Valenta Rudolf	Pathophysiologie, Infektiologie und Immunologie_370
FA648A0610	Automated Cell Detection in Osteoimmunology	Pietschmann Peter	Pathophysiologie, Infektiologie und Immunologie_370
FA623A0221	Entwicklung eines Multi-Parameter Immunoassay zum Nachweis des Impferfolges für Pneumokokken	Wiedermann-Schmidt Ursula	Pathophysiologie, Infektiologie und Immunologie_370
FA644A0405	Zukünftige stoffliche und mikrobiologische Herausforderungen für die kommunale Siedlungswasserwirtschaft	Sommer Regina	Pathophysiologie, Infektiologie und Immunologie_370
FA648A0310	The library of allergenic molecules	Valenta Rudolf	Pathophysiologie, Infektiologie und Immunologie_370
FA726A0601	Risikofaktoren und Arbeitssituation von Gesundheitspersonal in der COVID-19-Epidemie	Jordakieva Galateja	Physikalische Medizin, Rehabilitation und Arbeitsmedizin_726

FA726A0601	Risikofaktoren und Arbeitssituation von Gesundheitspersonal in der COVID-19-Epidemie	Jordakieva Galateja	Physikalische Medizin, Rehabilitation und Arbeitsmedizin_726
FA621A0601	Zusammenarbeitsvereinbarung "Apeiron Biologics AG"	Schabbauer Gernot	Physiologie und Pharmakologie_350
FA625A1002	Präzisionshistologie pathologischer Prozesse mittels künstlicher Intelligenz	Schmid Johannes	Physiologie und Pharmakologie_350
FA641A1301	A research platform for the preclinical development of future peptide drug candidates	Hellinger Roland	Physiologie und Pharmakologie_350
FA641A1301	A research platform for the preclinical development of future peptide drug candidates	Hellinger Roland	Physiologie und Pharmakologie_350
FA625A0903	Novel coagulation-dependent mechanisms of liver regeneration to detect and prevent liver dysfunction after partial hepatectomy	Assinger Alice	Physiologie und Pharmakologie_350
FA641A1301	A research platform for the preclinical development of future peptide drug candidates	Hellinger Roland	Physiologie und Pharmakologie_350
FA641A0604	Imaging the functional and molecular impact of Poly-unsaturated fatty acids on dopamine -dependent cognitive functions: a combined (11C)-(+)-PHNO PET/MRI study at different stages of cognitive impairment	Sitte Harald	Physiologie und Pharmakologie_350
FA621A0601	Zusammenarbeitsvereinbarung "Apeiron Biologics AG"	Schabbauer Gernot	Physiologie und Pharmakologie_350
FA641A1201	NEUROtransmitter TRANSPORTERS: from single molecules to human pathologies (Neuro Trans)	Stockner Thomas	Physiologie und Pharmakologie_350
FA763C0120	EUROPEAN STUDY ON RISK FACTORS FOR VIOLENCE IN MENTAL DISORDERS AND FORENSIC CARE: A MULTICENTRE PROJECT	Wancata Johannes	Psychiatrie und Psychotherapie_763
FA763B0446	A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder	Frey Richard	Psychiatrie und Psychotherapie_763

FA763B0444	A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar Disorder Who are Early in their Illness" or "A Phase 3 Study to Assess the Long-Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder	Frey Richard	Psychiatrie und Psychotherapie_763
FA763C0404	"EU FP7 PSYSCAN Translating neuroimaging findings from research into clinical practice"	Wancata Johannes	Psychiatrie und Psychotherapie_763
FA763B1001	Imaging the functional and molecular impact of poly-unsaturated fatty acids on dopamine-dependent cognitive functions: a combined [11C]-(+)-PHNO PET/MRI study at different stages of cognitive impairment	Willeit Matthäus	Psychiatrie und Psychotherapie_763
FA763B1101	Eine globale, prospektive, multizentrische Beobachtungsstudie nach dem Inverkehrbringen (Post-Market) zur Beurteilung der kurz-, mittel- und langfristigen Wirksamkeit und Effizienz der VNS Therapy® als Zusatzbehandlung bei Patientinnen und Patienten mit schwer behandelbarer Depression	Frey Richard	Psychiatrie und Psychotherapie_763
FA766A0501	Exploring Experiences of Young Adults with the 22q11 Deletion Syndrome: A Pilot Study	Löffler-Stastka Henriette	Psychoanalyse und Psychotherapie_766
FA766A0207	Krisenintervention für Menschen mit Migrationshintergrund und/oder Fluchterfahrung	Kapusta Nestor	Psychoanalyse und Psychotherapie_766
FA766A0501	Exploring Experiences of Young Adults with the 22q11 Deletion Syndrome: A Pilot Study	Löffler-Stastka Henriette	Psychoanalyse und Psychotherapie_766
	Bewusst Trinken - Förderung eines gesunden Trinkverhaltens durch innovative Peer-Education am Setting Schule	Winzer Eva	Public Health_380
	New Options for Resilient Measures for human health and well-being in the construction industry under climate change in Austria	Haluza Daniela	Public Health_380
FA646A0501	Konzeption und Aufbau des Schnittstellenmanagements im Rahmen des Projektes "HEPA Wien"	Lackinger Christian	Public Health_380
FA646A0701	WE-Project: Promoting Workplace Equality for LGBT + Q+Youth	Grabovac Igor	Public Health_380

UE64606002	Der Einfluss soziodemografischer Faktoren auf die Teilnahme am Österr. Brustkrebs-Früherkennungsprogramm (BKFP)	Rieder Anita	Public Health_380
FA636A0602	National Healthcare Systems Changes and Challenges - Access, Inequity and Socio-Economic Inequality, a Comparison between Kenya and Zambia	Jirovsky Elena	Public Health_380
FA647A0519	Flexibler NutzerInnenkomfort in viertelstündlich CO2-neutralen Plusenergiequartieren	Hutter Hans-Peter	Public Health_380
FA656A0201	SOFTVETS - Collaboration within the ERASMUS+ Program Projekt	Hladschik-Kermer Birgit	Public Health_380
FA636A0601	Psychosoziale und medizinische Betreuung von Patientinnen mit weiblicher Genitalverstümmelung	Jirovsky Elena	Public Health_380
FA646A0209	externe Evaluierung des Gesundheitsförderungsprojektes „HEPA Oberösterreich“. HEPA Oberösterreich ist ein Projekt zur Förderung der körperlichen Aktivität von Personen mit einem BMI 30-35 kg/m ² und von Typ 2 Diabetikern in Oberösterreich. Der genannte Zielgruppe wird ermöglicht, an einem qualitätsgesicherten Bewegungsprogramm von ASKÖ, ASVÖ oder Sportunion (im ersten Semester; 12 Einheiten) kostenfrei teilzunehmen. Die Kooperation zwischen der SVA und der MedUni Wien dient der Evaluierung des Projektes und der wissenschaftlichen Publikation.	Dorner Thomas Ernst	Public Health_380
FA646A0402	SARS CoV-2: Mental Health in Österreich	Niederkrotenthaler Thomas	Public Health_380
FA646A0701	WE-Project: Promoting Workplace Equality for LGBT + Q+Youth	Grabovac Igor	Public Health_380
FA636A0502	Studienlage zu den in Österreich am häufigsten verordneten potentiell inadäquaten Medikamenten für ältere Menschen	Sönnichsen Andreas	Public Health_380
FA646A0501	Konzeption und Aufbau des Schnittstellenmanagements im Rahmen des Projektes "HEPA Wien"	Lackinger Christian	Public Health_380
FA646A0601	Externe Evaluierung des Projektes "HEPA Oberösterreich" für das Jahr 2020	Kapan Hassan Ali	Public Health_380
FA636A0406	Latido-Telemedizin	Hoffmann Kathryn	Public Health_380
FA636A0507	Rechercheservice Evidenzbasierte Medizin (REM)	Sönnichsen Andreas	Public Health_380

FA636A0601	Psychosoziale und medizinische Betreuung von Patientinnen mit weiblicher Genitalverstümmelung	Jirovsky Elena	Public Health_380
FA646A0214	Review zum Thema E-Zigaretten, Tabakerhitzer	Dorner Thomas Ernst	Public Health_380
FA646A0213	Durchführung von Projekten und Maßnahmen im Sinne der „HEPA Strategie“. Zum jetzigen Zeitpunkt umfasst das konkret Aktivitäten betreffend „HEPA Steiermark“, „HEPA Oberösterreich“, „HEPA Burgenland“, „HEPA Kärnten“ und „HEPA Wien“.	Dorner Thomas Ernst	Public Health_380
FA646A0110	Pfade für Diagnostik, Behandlung und Zuweisung von geriatrischen Patient/innen mit Depressio, ausgehend von einer auffälligen GDS-4	Rieder Anita	Public Health_380
FA647A0701	Einfluss ernährungspädagogischer Interventionen auf Ernährungswissen und -verhalten bei MultiplikatorInnen in Kinderdörfern, die 'Kenwood Good Food Ernährungsstudie'	Hutter Hans-Peter	Public Health_380
	„A phase II, open label, randomized, parallel arm study of NIS793 (with and without spartalizumab) in combination with SOC chemotherapy gemcitabine/nab-paclitaxel, and gemcitabine/nab-paclitaxel alone in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)“	Hacker Marcus	Radiologie und Nuklearmedizin_771
FA771B0306	Intrakranielle Blutungen	Herold Christian	Radiologie und Nuklearmedizin_771
FA771B1301	EU H2020 Big Data for Medical Analytics	Prosch Helmut	Radiologie und Nuklearmedizin_771
	DISSECT-N	Funovics Martin	Radiologie und Nuklearmedizin_771
	Longterm follow up and mortality rate of patients of the Freeway Stent Study	Loewe Christian	Radiologie und Nuklearmedizin_771
FA771B1201	Somatom Force	Apfalter Paul	Radiologie und Nuklearmedizin_771
FA771B0305	Somatom Force	Herold Christian	Radiologie und Nuklearmedizin_771
FA771D0801	Somatom Force	Scherthner Rüdiger	Radiologie und Nuklearmedizin_771
FA771E1401	Validation of MR ChondralHealth-derived morphometric analysis and GLCM texture analysis using cadaver knees	Juras Vladimir	Radiologie und Nuklearmedizin_771

FA771E1301	A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab for the Prevention of Recurrence of Nasal Polyps Following Surgical Removal in Patients with Chronic Rhinosinusitis with Nasal Polyps (OXALIS)	Czerny Christian	Radiologie und Nuklearmedizin_771
FA771G0225	Identifizierung von ED-B Fibronectin an Gewebeproben (Onkologie und Kardiovaskular) durch immunhistologische Aufarbeitung mit ED-B Affilin.	Hacker Marcus	Radiologie und Nuklearmedizin_771
FA771B0306	Intrakranielle Blutungen	Herold Christian	Radiologie und Nuklearmedizin_771
FA771G0225	Identifizierung von ED-B Fibronectin an Gewebeproben (Onkologie und Kardiovaskular) durch immunhistologische Aufarbeitung mit ED-B Affilin.	Hacker Marcus	Radiologie und Nuklearmedizin_771
FA771G0255	EPIK-B3: A Phase III, multicenter, randomized, doubleblind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nabpaclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation	Hacker Marcus	Radiologie und Nuklearmedizin_771
FA771G0254	EPIK-B3: A Phase III, multicenter, randomized, doubleblind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nabpaclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation	Hacker Marcus	Radiologie und Nuklearmedizin_771
	Seattle Genetics Phase 3 Study in LA/M HER2+ Breast Cancer (SGTUC-016)	Loewe Christian	Radiologie und Nuklearmedizin_771
	SIRONA-Study - Head-to-Head Comparison of SIROLimus versus Paclitaxel Drug-Coated Balloon Angioplasty in the Femoropopliteal Artery	Wolf Florian	Radiologie und Nuklearmedizin_771

	Power PICC Prospective Observational PMCF Study	Waneck Fredrik	Radiologie und Nuklearmedizin_771
FA771E0506	Machine Learning for Phenotype Identification and Prediction	Langs Georg	Radiologie und Nuklearmedizin_771
FA771G0253	Kostendämpfungsoptionen in der Neuronuklearmedizin	Hacker Marcus	Radiologie und Nuklearmedizin_771
FA771B1302	Lungcast 2 - Lung disease progression and treatment response forecast from multimodal data" ("Study") (BI study number 1199-0416)	Prosch Helmut	Radiologie und Nuklearmedizin_771
FA771G0224	"An international multi-center, open-label study to evaluate safety, tolerability, biodistribution, dosimetry and preliminary efficacy of ¹⁷⁷ Lu-OPS201 for the therapy of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP NETs)"	Hacker Marcus	Radiologie und Nuklearmedizin_771
FA771D0510	BMS CA224-020- A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors	Wolf Florian	Radiologie und Nuklearmedizin_771
FA771D0509	BMS CA224-020- A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors	Wolf Florian	Radiologie und Nuklearmedizin_771
FA771B0420	KLINISCHE STUDIE ZUR BEWERTUNG DER DIAGNOSTISCHEN GENAUIGKEIT DER KONTRASTVERSTÄRKTEN TOMOSYNTHESE IM VERGLEICH ZUR KONTRASTVERSTÄRKTEN MAMMOGRAPHIE	Helbich Thomas	Radiologie und Nuklearmedizin_771
FA771B0305	Somatom Force	Herold Christian	Radiologie und Nuklearmedizin_771

FA771G0313	Validation of the analytical methods and the performance of QC/radiosynthesis of PET radiopharmaceuticals for measurement with the Research-PET-Scanner and of radiation protection measures within the research programme PL2 of the LBI research programme. This validation process includes all human resources, materials and methods involved in the setup of the respective radiosyntheses, the QC-assays and the underlying data provided for the submission and approval of the ethical votes	Wadsak Wolfgang	Radiologie und Nuklearmedizin_771
FA771B0848	A Phase 3 randomized, controlled, open-Label study of selinexor, bortezomib, and dexamethasone (SVD) versus bortezomib and Dexamethasone (VD) in Patients with relapsed or refractory multiple Myeloma (RRMM)	Herold Christian	Radiologie und Nuklearmedizin_771
FA771B0847	A Phase 2b, Open-Label, Single-Arm study of Selinexor (KPT-330) plus low-dose Dexamethasone (Sd) in Patients with Multiple Myeloma Previously treated with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an anti-CD38 Monoclonal Antibody (mAb) and Refractory to Prior Treatment with GLucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor and an anti-CD38 mAb	Herold Christian	Radiologie und Nuklearmedizin_771
FA771B0826	Phase 3, prospective, randomized, multi-center clinical study comparing the safety and efficacy of BAX 855 following PK-guided prophylaxis targeting two different FVIII trough levels in subjects with severe Hemophilia A	Herold Christian	Radiologie und Nuklearmedizin_771
FA771B0821	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation	Herold Christian	Radiologie und Nuklearmedizin_771
FA771B0820	A Multicenter, Single-arm, Open-label Study with Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Refractory or Relapsed and Refractory Multiple Myeloma	Herold Christian	Radiologie und Nuklearmedizin_771

FA771B0416	Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer	Helbich Thomas	Radiologie und Nuklearmedizin_771
FA771G0239	A trial investigating the effect of semaglutide on atherosclerosis in patients with cardiovascular disease and type 2 diabetes	Hacker Marcus	Radiologie und Nuklearmedizin_771
FA771G0240	A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG 160 in Subjects With Metastatic Castration-resistant Prostate Cancer	Hacker Marcus	Radiologie und Nuklearmedizin_771
FA771B0870	COLLABORATION AGREEMENT CONCERNING RESEARCH AND DEVELOPMENT WITH RESPECT TO THE DEVELOPMENT OF MACHINE LEARNING AND COMPUTER-ASSISTED DIAGNOSTICS MODELS BASED ON PRIMOVIST MR LIVER IMAGES	Herold Christian	Radiologie und Nuklearmedizin_771
FA771B0871	Doppelblinde, randomisierte, placebokontrollierte Phase-III-Studie zum Vergleich von Nor-Ursodeoxycholsäure-Kapseln versus Placebo bei der Behandlung von primär sklerosierender Cholangitis“ (nachfolgend „NUC-5 / PSC“ genannt	Herold Christian	Radiologie und Nuklearmedizin_771
FA771G0251	„A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease“	Hacker Marcus	Radiologie und Nuklearmedizin_771
FA771B0846	Lung disease Progression and Treatment Response forecast	Herold Christian	Radiologie und Nuklearmedizin_771
FA771E1102	MRSI im Gehirn	Hangel Gilbert Johannes	Radiologie und Nuklearmedizin_771
FA771E0507	Medical Images	Langs Georg	Radiologie und Nuklearmedizin_771
FA771B0419	ABCSG 52 / ATHENE: An open-label, two-arm, randomized, single-stage phase II study of ATezolizumab in combination with dual HER2 blockade plus epirubicin as NEOadjuvant therapy for HER2-positive early breast cancer	Helbich Thomas	Radiologie und Nuklearmedizin_771

FA771G0250	A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Of Ipatasertib In Combination With Atezolizumab And Paclitaxel As A Treatment For Patients With Locally Advanced Unresectable Or Metastatic Triple-Negative Breast-Cancer"	Hacker Marcus	Radiologie und Nuklearmedizin_771
FA771B0808	Unverblindete, multizentrische Phase IIIb- Studie zur Beurteilung der Langzeitwirksamkeit und -sicherheit von AOP2014 bei Patienten mit Polycythaemia vera, die an der Studie PROUD-PV teilgenommen haben.	Herold Christian	Radiologie und Nuklearmedizin_771
FA771B0853	Multicenter prospective, randomized study comparing PillCam Crohn's capsule endoscopy to ileocoloscopy (IC) plus MRE for detection of active CD in the small bowel and colon in subjects with known CD and mucosal disease (the BLINK -Study)	Herold Christian	Radiologie und Nuklearmedizin_771
FA771D0508	"TOBA III - Tack Optimized Drug Coated Balloon Angioplasty in the Superficial Femoral and Proximal Popliteal Arteries Using the Tack Endovascular System™- Protocol Number: CA 0135"	Wolf Florian	Radiologie und Nuklearmedizin_771
FA771B0869	A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy	Herold Christian	Radiologie und Nuklearmedizin_771
FA771B0845	A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Amphinex-induced Photochemical Internalisation (PCI) of Gemcitabine followed by Gemcitabine/Cisplatin Chemotherapy in Patients with Advanced Inoperable Cholangiocarcinomas	Herold Christian	Radiologie und Nuklearmedizin_771

FA771G0249	A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AT HIGH RISK OF RECURRENCE AFTER SURGICAL RESECTION OR ABLATION	Hacker Marcus	Radiologie und Nuklearmedizin_771
FA771B0868	A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects with T-Cell Prolymphocytic Leukemia	Herold Christian	Radiologie und Nuklearmedizin_771
FA771G0252	Heterogenitätsanalysen mittels PET/CT und PET/MRT sowie konventionellen nuklearmedizinischen Aufnahmen (planar, SPECT, SPECT/CT) zur Vorhersage von Gewebsbeschaffenheit, Therapieansprechen und Überleben	Hacker Marcus	Radiologie und Nuklearmedizin_771
FA771B0415	Integrated Decision Support - Breast Cancer	Helbich Thomas	Radiologie und Nuklearmedizin_771
FA771B0502	Deciphering breast cancer heterogeneity and Tumor microenvironment with correlative imaging	Pinker-Domenig Katja	Radiologie und Nuklearmedizin_771
FA771B0867	Eine multizentrische, unverblindete Phase-I-Studie zur Untersuchung der Sicherheit, Verträglichkeit, Wirksamkeit und Pharmakokinetik von DCC-2618 bei Patienten mit fortgeschrittenen malignen Erkrankungen	Herold Christian	Radiologie und Nuklearmedizin_771
FA771B0411	EU EU-Projekt HYPMED	Helbich Thomas	Radiologie und Nuklearmedizin_771
FA771B0866	A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Ponatinib-3001	Herold Christian	Radiologie und Nuklearmedizin_771

FA771E0319	Multicenter, randomized, placebo-controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute noncardioembolic ischemic stroke	Prayer Daniela	Radiologie und Nuklearmedizin_771
FA771B0865	An open label, long term safety trial of spesolimab treatment in patients with fistulising Crohn's disease who have completed previous spesolimab trials	Herold Christian	Radiologie und Nuklearmedizin_771
FA771D0317	Retrospektive 5-Jahres Sicherheitsanalyse der BIOLUX P-I und P-II Studien in Probanden mit Revascularisierung der Infringuinalarterien	Loewe Christian	Radiologie und Nuklearmedizin_771
FA771B0864	A Phase 3, Multicenter, Open-Label, randomized Study to evaluate the efficacy and safety of Fedratinib compared to Best available Therapy in subjects with DIPS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and preciously treated with ruxolitinib (FREEDOM 2)	Herold Christian	Radiologie und Nuklearmedizin_771
FA771B0418	A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Of Ipatasertib In Combination With Atezolizumab And Paclitaxel As A Treatment For Patients With Locally Advanced Unresectable Or Metastatic Triple-Negative Breast-Cancer	Helbich Thomas	Radiologie und Nuklearmedizin_771
FA771G0247	N.c.a. Lu-177 in radiopharmazeutischen Präparationen - operatives Labormanagement.	Hacker Marcus	Radiologie und Nuklearmedizin_771
FA771E0504	Large Data Analyses	Langs Georg	Radiologie und Nuklearmedizin_771
FA771B0412	EU EU-Projekt MURAB	Helbich Thomas	Radiologie und Nuklearmedizin_771
FA771B1201	Somatom Force	Apfaltrer Paul	Radiologie und Nuklearmedizin_771
FA771D0801	Somatom Force	Scherthner Rüdiger	Radiologie und Nuklearmedizin_771

FA771B0417	A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in the Treatment of High-risk, Stage II-III Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER-2) Breast Cancer Checkmate 7FL: CHECKpoint pathway and nivolumab clinical Trial Evaluation 7FL)	Helbich Thomas	Radiologie und Nuklearmedizin_771
FA771B1501	AGMT_ERCC1 - Biomarker directed treatment in metastatic colorectal cancer	Tamandl Dietmar	Radiologie und Nuklearmedizin_771
FA771B0863	A Phase IB/II open-Label, multicenter, randomized controlled study investigating the safety, tolerability, pharmacokinetics, and efficacy of mesunetuzumab (BTCT4465A) in combination with chop or chppolatunumab vedotin in patients with b-cell non-hodgkin lymphoma	Herold Christian	Radiologie und Nuklearmedizin_771
FA771B0862	Evaluation of the efficacy and safety of GS-5745 as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methrexate Regimen in subjects with moderate to Severe Rheumatoid Arthritis	Herold Christian	Radiologie und Nuklearmedizin_771
FA771G0246	A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk	Hacker Marcus	Radiologie und Nuklearmedizin_771
FA771D0523	PMCF-001 - Post-Market Clinical Follow Up of Rotarex®SCatheter	Wolf Florian	Radiologie und Nuklearmedizin_771
FA771B0861	Double-blind, randomised, Placebo-controlled Phase IIb Trial on the efficacy and safety of norursodeoxycholic acid tablets in patients with non-alcoholic steatohepatitis	Herold Christian	Radiologie und Nuklearmedizin_771
FA771E0504	Large Data Analyses	Langs Georg	Radiologie und Nuklearmedizin_771

FA771B0852	A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA®) VERSUS SUNITINIB (SUTENT®) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA	Herold Christian	Radiologie und Nuklearmedizin_771
FA771B0851	A Phase II siingle arm clinical Trial of Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastasic or advanced Renal Cell Carcinoma	Herold Christian	Radiologie und Nuklearmedizin_771
FA771B0844	A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multi Center, Single-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of DS-1040b when Addes to Standard of Care Anticoagulation Therapy in Subjects with Acute Submassive Pulmonary Embolism	Herold Christian	Radiologie und Nuklearmedizin_771
FA771B0835	A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone or with Lenalidomide plus R CHOP in Subjects With Previously Untreated, High Risk Diffuse Large B Cell Lymphoma	Herold Christian	Radiologie und Nuklearmedizin_771
FA771B0819	A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ETMF)	Herold Christian	Radiologie und Nuklearmedizin_771
FA771B0809	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (ML N9708) Maintenance Therapy in Patients with Multiple Myeloma Following Autologous Stem Cell Transplant	Herold Christian	Radiologie und Nuklearmedizin_771
FA774A0203	“Tailored AXillary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS). A multicenter randomized open labeled phase III trial” (“Studie”).	Kauer-Dorner Daniela	Radioonkologie_774

FA774A0601	"EU European Joint Programme for the Integration of Radiation Protection Research - CONCERT ('action') NUMBER — 662287 — CONCERT"	Widder Joachim	Strahlentherapie_774
FA774A0302	AGMT_HNO-2: Randomisierte Phase II Pilot Studie: Induktionstherapie mit Docetaxel, Cisplatin und Cetuximab versus Docetaxel, Cisplatin und 5 FU gefolgt von Radioimmuntherapie mit Cetuximab bei lokal fortgeschrittenen oder inoperablen Kopf-Hals Tumoren	Altorjai Gabriela	Strahlentherapie_774
FA774A0702	A multi-centre, open-label, single-arm, dose-finding phase I/II study to evaluate safety, tolerability, dosing schedule, and preliminary efficacy of carrier-added 4-L-[131I]iodo-phenylalanine (131I-IPA), administered as single or repetitive injections in patients with recurrent glioblastoma multiforme (GBM), concomitantly to 2nd line external radiation therapy (XRT) - IPAX-1Study	Dieckmann Ute	Strahlentherapie_774
FA774A0901	EUROSTARS-2 CoD 9: 12326 ILLUMINUS - The ILLUMINUS software platform for AI based MRI only radiotherapy treatment planning	Georg Dietmar	Strahlentherapie_774
FA670A0103	"Vergleich der Genauigkeit digitaler versus konventioneller Implantat-getragener Kronenversorgungen: eine klinische Studie"	Schedle Andreas	Universitätszahnklinik_670
FA670G0103	Behandlung von hypersensiblen, strukturgeschädigten Molaren mit MIH mittels Sealing-Therapie - eine Pilotstudie	Bekes Katrin	Universitätszahnklinik_670
FA670F0202	Osteogenic potential of different Ti surfaces	Rausch-Fan Xiaohui	Universitätszahnklinik_670
	Surefil one als Amalgamersatz für Klasse II Füllungen im Studentenkurs	Schedle Andreas	Universitätszahnklinik_670
FA670A0106	"Mikromorphologische Untersuchung von gefüllten Zähnen mittels μ CT"	Schedle Andreas	Universitätszahnklinik_670
FA670A0105	"REM-Untersuchung des Zahnschmelzes von Rinderzähnen nach Ultraschallbehandlung"	Schedle Andreas	Universitätszahnklinik_670
FA670A0104	Influence of different surface treatments of zirconia on the adhesion of self adhesive cements	Schedle Andreas	Universitätszahnklinik_670

FA670G0103	Behandlung von hypersensiblen, strukturgeschädigten Molaren mit MIH mittels Sealing-Therapie - eine Pilotstudie	Bekes Katrin	Universitätszahnklinik_670
	A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical Cystectomy", 17000139BLC3001	Shariat Shahrokh	Urologie_743
	DAROL: Nicht-interventionelle Studie zu Darolutamid bei Patienten mit nicht-metastasiertem, kastrationsresistentem Prostatakarzinom (nmCRPC)	Shariat Shahrokh	Urologie_743
FA743A0248	Eine unverblindete Folgestudie zur Sicherstellung der fortlaufenden Behandlung mit Darolutamid für Prüfungsteilnehmer aus vorherigen von Bayer gesponserten Studien	Shariat Shahrokh	Urologie_743
FA743A0602	Molecular Classification of muscle-invasive bladder cancer patients scheduled for radical cystectomy using a single-sample transcriptomic consensus classifier	Hassler-Di Fratta Melanie	Urologie_743
FA743A0111	A phase III, multicenter, randomized study of Atezolizumab (Anti-PD-L1 Antibody) in combination with Enzalutamide versus Enzalutamide alone in patients with metastatic castration-resistant prostate cancer after failure of an Androgen synthesis inhibitor and failure of, ineligibility for, or refusal of a taxane regimen	Kramer Gero	Urologie_743
FA743A0247	A Phase 3, Randomized, Double-blind Trial of Nivolumab in Combination with Intravesical BCG versus Standard of Care BCG Alone in Participants with High-risk Non-muscle Invasive Bladder Cancer That Is Persistent or Recurrent After Treatment with BCG	Shariat Shahrokh	Urologie_743
FA743A0246	An open-label multi-cohort Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-02)	Shariat Shahrokh	Urologie_743

FA743A0245	Einarmige Open-Label-Studie der Phase 2 mit monoklonalem Anti-PD1 MK-3475-Antikörper (Pembrolizumab) bei Patienten mit muskelinvasivem rothelkarzinom vor radikaler Zystektomie	Shariat Shahrokh	Urologie_743
FA743A0244	Eine einarmige, multizentrische, internationale prospektive Studie zur Bewertung der Wirksamkeit des vorübergehend implantierbaren Medizinprodukts der Firma Medit-Tate (iTind) bei Patienten mit benigner Prostatahyperplasie (BPH).	Shariat Shahrokh	Urologie_743
FA711D0133	Platelet Rich Fibrin in combination with topical antibiotics	Thalhammer Florian	Urologie_743
FA743A0243	A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991), MK-3475-991	Shariat Shahrokh	Urologie_743
FA743A0226	Prostate Cancer Outcomes (PCO) Studie - Eine globale Untersuchung zur Messung und Verbesserung der Ergebnisqualität beim lokal begrenzten Prostatakarzinom	Shariat Shahrokh	Urologie_743
	Dunkelzifferstudie-Prävalenzstudie SARS-CoV-2 - 3. Flight	Weseslindtner Lukas	Virologie_307
FA690A0402	TBE in Austria - Extended assessment of clinical course including sequelae and vaccination status of virologically verified TBE cases based on active surveillance	Holzmann Heidemarie	Virologie_307
FA690A0703	Durchführung von Analysen von Proben mit der klinischen Studie BS-01	Redlberger-Fritz Monika	Virologie_307
FA690A0203	Diagnostisches Influenzanezwerk Österreich Grippesaison 2011/2012	Redlberger-Fritz Monika	Virologie_307
FA690A0503	Comparison of TTV PCR assays	Puchhammer Elisabeth	Virologie_307
FA103A0006	RAISE: Dynamics of airway microbiota at pulmonary exacerbation in cystic fibrosis	Widder Stefanie	Vizerektorat für Forschung und Innovation_108

2. Stück Mitteilungsblatt, Studienjahr 2020/2021,
ausgegeben am 25.11.2020, Nr. 2

101

Markus Müller
Rektor